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Abstract 
 
 A resurgence of interest in vitamin D research has led to the discovery that 
it plays a role in an unexpectedly large number of biological processes, and that 
reduced levels of this hormone are implicated in a range of diseases. In fact, it is 
estimated that vitamin D is involved in the regulation of 3% of the human genome. 
Two genes containing the target sequence indicative of vitamin D regulation are 
those encoding LL-37 and hBD-2. These antimicrobial peptides are integral 
components of the innate immune system and act as natural antibiotics to help 
combat infection.  
The respiratory epithelium exposes a large surface area to environmental 
pathogens, making the innate immune response extremely important in its defence. 
Microbial infection of the respiratory tract is the cause of pneumonia, and is 
implicated in cases of COPD exacerbation. This study aimed to determine 
whether a relationship existed between vitamin D, LL-37 and hBD-2 in 185 
patients admitted to Waikato hospital with either condition. It was hypothesised 
that low vitamin D would correlate with reduced peptide levels, and that this 
would be associated with increased infection severity and higher mortality rates. 
Peptide concentrations in patient plasma were measured by indirect 
ELISA and compared to 25D levels. Statistical analysis revealed no significant 
associations between vitamin D status, peptide levels and severity, but did show 
increased mortality in individuals with severe vitamin D deficiency or low LL-37.  
Based on the significance of LL-37 as a predictor of mortality (particularly 
in COPD), development of a plasma screening method using MALDI-TOF mass 
spectrometry was attempted, as a potential means of identifying patients most at 
risk. The success of this method was limited however, as the low abundance and 
small size of the mature peptide caused detection problems. 
A protocol for assessing the vitamin D binding protein (DBP) genotype 
was developed, as it influences baseline 25D levels and response to 
supplementation. The association between low vitamin D and mortality suggests 
that supplementation could improve survival rates and, as the supplement dose 
required for effectiveness is genotype-dependent, this method could allow 
determination of the appropriate amount to administer to at-risk individuals.
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1. Introduction 
1.1 Vitamin D 
Often referred to as the “sunshine vitamin”1, vitamin D is actually a 
hormone with a multitude of biological roles in the body2. The discovery of 
vitamin D has largely been linked to studies on the disease rickets, which was first 
described in the 5th Century, BC. Since then, observations that rickets is less 
common among rural children than those living in cities - particularly in areas of 
heavy pollution, led to the recognition that sunlight plays an important role in the 
prevention and treatment of the disease. The agent responsible for this protective 
effect was later identified as vitamin D3. 
The importance of vitamin D in bone health has therefore been known for 
some time, but an increasing number of studies are beginning to show that it also 
plays a role in a wide range of other processes, such as in reducing the risk of 
infection. Unlike most vitamins, which function as general immunological agents, 
vitamin D can act specifically, and appears to be an integral component of the 
immune system4. A 1932 paper5 recognised that much of the time lost due to 
illness at an industrial company was as a result of common colds, and that regular 
doses of cod-liver oil (which contains both vitamins A and D) may help to reduce 
this. They also noted that their experiment spanned “the season of greatest 
prevalence of colds and minimum sunlight and resistance to colds”5, indicating 
that even at this early date, a connection was made between sunlight, vitamin D 
and immunity. 
 
1.1.1 Sources and synthesis 
In humans, vitamin D can be obtained in two ways: through the diet, and 
by synthesis in the body1; 3. Some foods naturally contain vitamin D (e.g. oily 
fish), while others (e.g. some milks and cereals) are fortified with the vitamin. 
Dietary sources however, are generally only minor contributors to the net daily 
intake of vitamin D1. 
The main source of vitamin D is synthesis from a precursor called  
7-dehydrocholesterol, which is present in the skin. This precursor absorbs solar 
ultraviolet radiation in the UVB range (280-320 nm)6, and uses the energy 
obtained to undergo transformation and subsequent isomerisation. The resulting 
Introduction  13 
compound, vitamin D3, is released into the circulation where it is transported by 
the vitamin D-binding protein1; 3.  
Once in the bloodstream, both diet-derived and synthesised vitamin D3 
follow the same downstream pathway, involving two hydroxylation steps (Figure 
1.1). The first of these, catalysed by 25-hydroxylase (CYP27A1), takes place in 
the liver and forms 25-hydroxyvitamin D3 (25(OH)D or 25D), while the second, 
catalysed by 1α-hydroxylase (CYP27B1), is carried out in the kidneys and 
generates 1,25-dihydroxyvitamin D3 (1,25(OH)2D or 1,25D), the active 
metabolite1; 3; 7.  
 
Figure 1.1 – Schematic representation of the synthesis and regulation of 
vitamin D, as published by Deeb et al.8 
 
1.1.2 Factors influencing synthesis 
 Due to the fact that UVB radiation is required to catalyze the first step of 
the vitamin D synthesis pathway, any factor that influences the amount of UVB 
contacting the skin will also impact the capacity for vitamin D production. Such 
factors include: latitude, season, time of day, sunscreen use, skin pigmentation, 
culture and lifestyle. Additional factors, such as age, also have an effect1; 3; 6.  
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i. Latitude, season and time of day 
 Ultraviolet (UV) radiation travels to earth on an angle called the zenith 
angle, which is influenced by factors such as latitude, season and time of day. At 
smaller angles (i.e. lower latitudes, during summer, and between 10am and 3pm), 
the UV does not have as far to travel, and is therefore less likely to be absorbed by 
atmospheric molecules, such as ozone. Therefore, under these conditions, more 
UV will reach the earth surface, increasing the potential for vitamin D synthesis. 
For example, people living at the equator receive reasonably high levels of UV 
radiation all year round, while those at higher latitudes have lower levels. The 
amount of UV can be so low in these areas, particularly during winter, that little 
(if any) vitamin D can be synthesised1; 6. 
 
ii. Sunscreen use and skin pigmentation 
Sunscreen absorbs UVB photons, preventing them from entering the skin 
and catalysing vitamin D synthesis. Even low sun protection factor (SPF) 
sunscreens can block enough UV as to significantly reduce vitamin D production1.  
Melanin, the pigment that gives skin its colour, also absorbs UVB. 
Therefore, individuals with more of the pigment will produce less vitamin D than 
lighter-skinned individuals when exposed to the same amount of UV, for the same 
time1. This may explain why vitamin D deficiency is more common among 
darker-skinned groups2; 9. 
 
iii. Culture and lifestyle 
 Cultural beliefs may influence vitamin D production3. For example, 
women in some cultures wear clothes over their entire body, significantly 
reducing their UVB-dependent vitamin D synthesis. Lifestyle choices (e.g. staying 
indoors) have a similar effect, which may explain why vitamin D levels are 
especially low in elderly and sick individuals10; 11. 
 
iv. Age 
Another explanation for the high prevalence of vitamin D deficiency in the 
elderly is the fact that older people have less 7-dehydrocholesterol in their skin, 
and therefore have a reduced capacity to produce vitamin D1; 10; 11. 
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v. Conflicting messages 
Increased awareness about the dangers of UV, particularly in relation to 
skin cancer, has encouraged people to use sunscreen more often, and to seek 
shade or stay indoors between the hours of 10 am and 3 pm. While this does act to 
reduce the damaging effects of UV, it also limits vitamin D synthesis1. 
 
1.1.3 Vitamin D status 
Although 1,25D is the active metabolite and carries out most of the roles 
associated with vitamin D, 25D is the main form present in the circulation and has 
a longer half-life. In addition, 1,25D can be produced in response to parathyroid 
hormone (PTH). The levels of this hormone rise during vitamin D deficiency, 
resulting in high serum 1,25D levels, which could confound the true vitamin D 
status of an individual. For these reasons, measurement of the 25D concentration 
in the circulation is the accepted means of determining vitamin D status1; 3. 
Vitamin D deficiency is defined as a serum 25D level of less than 
20 ng/mL (50 nmol/L), while insufficient and sufficient vitamin D levels are 
classed as 20-32 ng/mL and >32 ng/mL, respectively11. The optimal level of 
vitamin D remains to be determined, and could lead to an increase in daily intake 
recommendations, which are currently: 200 IU/day for those aged <50 y; 
400 IU/day for those 50-70 y; and 600 IU/day for those >70 y1; 3; 11.  
The belief that these intake guidelines need to be raised is supported by a 
number of studies. For example, it has been shown that a circulating vitamin D 
concentration of 30 ng/mL can be maintained with a daily intake of 500-1000 IU11. 
However, this exceeds the highest current daily recommended intake, while only 
producing vitamin D levels on the borderline of insufficiency and sufficiency.  
Although a revision of daily adequate intake guidelines appears to be 
needed, determination of appropriate levels is difficult. Improved 
recommendations should not be supplied as an average for the general population, 
as this does not account for differences in an individual’s place of residence (e.g. 
latitude), the time of year, or the personal characteristics of that individual (e.g. 
age, skin colour) - factors which have been shown to significantly impact vitamin 
D levels3. 
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1.1.4 Mode of Action 
 1,25-dihydroxyvitamin D3 (1,25D) exerts many of its biological effects via 
the nuclear vitamin D receptor (VDR), which consists of ligand- and DNA-
binding domains. Upon entry to cells, 1,25D is transported to the nucleus where it 
binds in the ligand-binding domain of the VDR. This activates the receptor, 
allowing it to form a heterodimer with the retinoic X receptor (RXR). The DNA-
binding domain allows the VDR-RXR complex to bind to specific repeat 
sequences on the DNA molecule, called vitamin D response elements (VDREs). 
This initiates the binding of a range of other proteins, and leads to the formation 
of a complex with the ability to regulate the expression of VDRE-containing 
genes. Vitamin D response elements are found in the regulatory regions of target 
genes, and although they are often in close proximity to gene promoters, they 
have also been found up to 75 kb away9. 
Vitamin D receptors have been identified in a wide range of cells, tissues 
and organs, including the brain, colon, prostate3, breast, gonads, skin, pancreatic 
cells1, bone12, heart1; 3, and many immune cells such as T lymphocytes and 
macrophages9. This suggests a widespread involvement of vitamin D in processes 
throughout the body. In fact, the vitamin D pathway is estimated to be involved in 
the regulation of 3% of the human genome12. 
 
1.1.5 Problems associated with deficiency 
 Vitamin D deficiency is not uncommon. Worldwide, estimated cases 
approach 1 billion, and the risk of deficiency is particularly high during winter, in 
individuals with dark skin, and in the elderly13. As vitamin D appears to be 
involved in such a wide range of physiological processes, it is not surprising that 
deficiency can result in a multitude of problems.  
 An increasing number of studies are showing correlations between vitamin 
D and a diversity of diseases, ranging from bone disorders (e.g. rickets14), to 
cancer, cardiovascular and autoimmune diseases (e.g. multiple sclerosis)9. Of 
particular interest to this study is the role of vitamin D in the immune response to 
infection, particularly with respect to the respiratory tract. 
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1.2 Antimicrobial peptides 
Living organisms possess a wide range of defences to protect against 
microbial invasion, and these can be divided into innate and adaptive responses. 
The innate immune system is thought of as the “first line of defense”15, and is 
relatively non-specific, but always active. This means it is able to act immediately 
upon invasion, but lacks the specificity of the adaptive response (e.g. antibody 
production)16.  
One innate mechanism is the production of antimicrobial peptides (AMPs). 
These are small (15-45 amino acid) peptides, usually with a net positive charge. 
They can be found in many organisms, including invertebrates, and have many 
features which are conserved across these species17. 
The antibiotic activity of these peptides makes them candidates for future 
therapeutic drugs, especially since some have been shown to have activity against 
bacterial strains which are resistant to antibiotics currently in use15; 18. These 
peptides have also been shown to have a range of other functions besides direct 
microbial killing, making their role in the immune system even more important 
than initially realised15.  
 
1.2.1 Mode of action 
 Antimicrobial peptides (AMPs) have been detected in many bodily fluids 
and secretions, such as blood, saliva, semen and sweat, and in a wide range of 
cells throughout the body. Expression by the epithelial cells of the skin, airways, 
gastrointestinal and genitourinary tracts, allow AMPs to function as a barrier for 
the host, by intercepting pathogens at surfaces in direct contact with the 
environment15; 17; 18. 
These peptides have also been found in immune cells such as lymphocytes 
and monocytes, where they may act as chemoattractants for other immune cells, 
allowing up-regulation of the immune response at the site of infection15; 18. Other 
immune cell-associated AMPs play a role in the elimination of phagocytosed 
microorganisms, as in the case of the α-defensins present in azurophil granules of 
neutrophils15. 
Most antimicrobial peptides are thought to kill their targets by the 
disruption of cell membranes, and the basic structural aspects shared by most 
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AMPs aid in this mechanism of action. The net positive charges of the peptides 
attract them to the negatively-charged bacterial membranes, and their amphipathic 
nature facilitates insertion15; 17; 18. This leads to leakage of cell contents and cell 
lysis, and must occur quickly to combat the rapid multiplication rate of bacteria17.  
Bacteria are not the only target however, as AMPs can also act on other 
microorganisms that possess membranes, including enveloped viruses (e.g. human 
immunodeficiency virus, HIV) and some fungi15. To make this process selective 
for invading microorganisms and prevent self-damage to the host, AMPs do not 
attack membranes containing cholesterol, which is a principal component of 
eukaryotic cells17. 
Homeostatic levels of natural host flora can be maintained by the 
constitutive expression of some AMPs, while inducible expression acts to increase 
protection during infection17.  
 
1.2.2 Classes 
Antimicrobial peptides can be grouped into three main classes based on 
their structure. The first group contains peptides which do not have cysteine 
residues, so form linear α-helical structures (e.g. human cathelicidin, LL-37); the 
second includes peptides with cysteine residues arranged to form intramolecular 
disulphide bonds to give a β-sheet structure (e.g. human defensins); and peptides 
with a high proportion of a particular amino acid, such as arginine or proline, 
make up the third main group of antimicrobial peptides17; 18. 
In 2003, Boman17 stated that “defensins and LL-37 are the components 
most essential for protecting our adult life from bacterial infections”. Additionally, 
LL-37 has been found to act synergistically with the β-defensins19, and the genes 
encoding LL-37 and human β defensin-2 (hBD-2) peptides contain VDREs9. In 
accordance with these findings, the focus of this study will be on the cathelicidin 
and defensin peptide families, and in particular, LL-37 and hBD-2. 
 
1.3 Human cathelicidin 
Members of the cathelicidin family of antimicrobial peptides are 
characterised by an N-terminal region with a sequence akin to that of cathelin. 
This region, referred to as the cathelin-like domain, is highly conserved between 
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species. Such conservation is made even more remarkable when compared to the 
C-terminal antimicrobial domain, which varies not only between, but also within 
species. This is the case in many species (e.g. cattle, pigs), where a number of 
different cathelicidin peptides have been identified. Even the ancient hagfish has 
two cathelicidin genes, indicating that these peptides have been conserved across 
many generations. However, a few organisms, including mice and humans, have 
only a single cathelicidin gene each19; 20. 
The importance of this peptide and its proper regulation in humans is 
evident in patients with morbus Kostmann. These individuals lack LL-37 due to a 
genetic disorder, and their condition is fatal without treatment20. 
 
1.3.1 Structure and processing 
 The human cathelicidin gene contains four exons, and is located on 
chromosome three21. Exons 1-3 hold the information for the signal sequence and 
cathelin-like domain, while the antimicrobial region is encoded by exon 4 (Figure 
1.2). The product of this gene is a prepropeptide. After removal of the signal 
sequence, the propeptide hCAP-18 (human cathelicidin antimicrobial peptide) is 
produced20.  
 
 
 
 
Figure 1.2 – Basic structures of the human cathelicidin gene and precursor, 
modified from Ulrich et al.20 
 
Much of the cathelicidin synthesised in myeloid cells is targeted for 
storage in the granules of neutrophils22, but hCAP-18 has also been identified in a 
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wide range of body fluids (e.g. plasma, saliva), and epithelia (e.g. gut, respiratory 
tract)17; 18; 19. This epithelial expression can be induced in response to appropriate 
stimuli, and is often up-regulated during disease20; 23.  
In healthy individuals, hCAP-18 can be found in plasma at concentrations 
of 1.2-1.8 µg/mL. Retention of such levels would be damaging to the host if not 
for a factor in plasma that inhibits the antimicrobial and cytotoxic effects of the 
peptide24. Wang et al.25 identified this factor as apolipoprotein A-I, a 28 kDa 
protein that sequesters cathelicidin by binding to the antimicrobial region (LL-37), 
probably through interactions similar to those involved in binding to bacterial 
membranes.  
When the body is invaded by foreign organisms, inactive hCAP-18 can be 
converted to the mature peptide, which exhibits antimicrobial activity. This 
activation occurs when proteinase-3 cleaves off the cathelin-like domain26. The 
mature cathelicidin peptide produced is called LL-37, because it is 37 amino acid 
residues in length and begins with two Leucines, as shown in Figure 1.320.  
 
LLGDFFRKSK-­‐EKIGKEFKRI-­‐VQRIKDFLRN-­‐LVPRTES	  
 
Figure 1.3 – Amino acid sequence of LL-37 
 
The cationic nature of this peptide is evident when examining the ratio of 
positive to negative charges in the sequence, which add up to give a net charge of 
+6, at physiological pH20. 
 
1.3.2 Actions 
The actions of LL-37 can be separated into two broad groups: 
antimicrobial and signalling. The antimicrobial role of LL-37 is extremely 
important for the maintenance of adequate host protection, and is an integral part 
of the innate immune response. However, the activities of LL-37 are now known 
to extend past this, to a signalling role, where it may help to activate or enhance 
the adaptive immune response20. 
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i. Direct antimicrobial activity 
The human cathelicidin peptide has direct antimicrobial activity against a 
wide range of microorganisms, including Gram-positive and -negative bacteria, as 
well as some fungi and enveloped viruses19. As shown in Figure 1.4, it is thought 
to exert this antibiotic effect by binding to bacterial membranes, possibly forming 
a carpet-like layer which disrupts the membrane and leads to the formation of 
pores23; 27. This would cause leakage of cell contents and lysis of the invading 
organism, and may occur at epithelial surfaces or within phagocytic cells19. 
 
Figure 1.4 – Model of a possible mechanism of action for LL-37 on bacterial 
membranes, as published by Oren et al.27 
 
Physiological conditions seem to induce aggregation of LL-37, leading to 
oligomerization, but it is unclear whether the oligomers or monomers interact with 
the membranes20. 
 
ii. Other actions 
A number of other roles have also been suggested for LL-37. For example, 
it can act as a chemoattractant, to recruit T cells and leukocytes (e.g. neutrophils 
and monocytes) to infected areas. It can also stimulate the release of 
proinflammatory mediators from mast cells, and increase expression of 
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chemokines and their receptors, which leads to further recruitment of cells to the 
infected or inflamed site20; 28. 
Due to this ability to promote inflammation, the expression of LL-37 must 
be regulated to prevent an uncontrolled response. It is therefore important to note 
that this peptide can also regulate the expression of anti-inflammatory genes, and 
can itself bind to bacterial lipopolysaccharide (LPS) and neutralise it29. LPS is 
released from bacterial cell membranes when they lyse, and can cause the 
production of proinflammatory agents such as tumour necrosis factor- α (TNF-α), 
leading to endotoxemia (or ‘septic shock’)20; 28. Cirioni et al.29 showed that LL-37 
was more effective at reducing plasma LPS and TNF-α levels than the β-lactams 
commonly used to treat septic shock. 
These functions place LL-37 on the borderline of adaptive immunity, and 
may help to target this aspect of the immune response to the appropriate site20; 23. 
Based on its involvement in such a wide range of processes, it is not surprising 
that this peptide is so essential to host survival. 
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1.4 Human defensins 
Like the cathelicidin family, defensins can be found in a wide range of 
species, both vertebrate and invertebrate28, and this conservation shows the 
importance of these peptides in host defence30. Unlike the cathelicidins however, 
humans have many defensins, rather than just one, and they are separated into two 
subgroups: α-defensins and β-defensins28. 
Human defensin genes are found in a cluster on chromosome 831, but each 
subgroup is regulated differently32. Like the cathelicidins, both α- and β-defensin 
subfamilies are synthesised as precursor proteins, with a signal sequence, 
proregion, and antimicrobial domain (Figure 1.5). These precursors are processed 
to release the mature antimicrobial peptides21. 
 
Figure 1.5 – Basic structural comparison of defensin and cathelicidin 
precursors, as published by Kolls et al.30 
 
The mature peptides of both subgroups contain six cysteine residues, 
characteristic of defensins. This means that, although there is little homology 
between their primary sequences, they fold to form very similar β-sheet structures 
via the formation of three intramolecular disulphide bonds. Despite these 
structural similarities, there are several key features that distinguish each group. 
Firstly, the α-defensins are generally smaller, with 29-35 residues, as opposed to 
the 36-42 residues of the β-defensins. In addition, the cysteine pairings differ in 
each group, with bonds forming between cysteines 1-6, 2-4, and 3-5 in the α-
defensins, and 1-5, 2-4, and 3-6 in the β-defensins15; 18.  
 Another variation between the two classes is their location within the body. 
Human α-defensins are primarily found in the azurophil granules of neutrophils, 
where they are responsible for the killing of phagocytosed microorganisms. Based 
on this, they are often referred to as human neutrophil peptides (HNP 1-4), and are 
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synthesised in myeloid cells during neutrophil development. Two other α-
defensins (HD 5-6) are found in the granules of Paneth cells in the small 
intestine18; 31; 32. This containment inside granules is necessary for α-defensins, 
because they are toxic to the host17. 
The β-defensins on the other hand are much more widespread, and have 
been found in epithelial cells throughout the body18. Each β-defensin peptide has a 
different distribution, and varies in whether it’s expression is constitutive (e.g. 
hBD-1) or inducible31. 
The defensin that is the focus of this study, hBD-2 is found particularly in 
the skin, as well as in lung and tracheal epithelia, where it is thought to play a role 
in defending the airway mucosa. Expression of hBD-2 is strongly induced by 
bacterial stimuli (e.g. LPS) and inflammatory mediators (e.g. TNF- α)32. 
 
1.4.1 Actions 
Defensins are thought to exert a direct antimicrobial effect by binding to 
bacterial membranes, much like other cationic peptides (e.g. cathelicidin). It is 
uncertain how they carry out the killing reaction once bound, but permeabilization 
and pore formation are commonly suggested28; 31. However, a single mechanism 
for the antimicrobial effect of defensins is difficult to justify, as humans possess 
many different defensin peptides, and structural variation among these would 
surely affect their mode of action. It has been suggested that the tissue-dependent 
distribution of different defensins, places them in contact with organisms against 
which they are most effective31. 
Other activities have also been suggested for defensins. Many defensins 
are chemoattractants that aid in the recruitment of immune cells to sites of 
infection. For example, hBD-2 is chemotactic for mast cells, T lymphocytes, and 
various phagocytic cells. This can enhance the inflammatory response, adaptive 
immune response, and antimicrobial effect, respectively. In addition, defensins 
can bind to microbial antigens and deliver them to dendritic cells, leading to 
induction of adaptive immunity via stimulation of antigen-specific T-cells28. 
These AMPs can also induce TNF-α and interleukin-1 (IL-1) production28, 
leading to increased expression of defensin genes (e.g. hBD-2)32. Therefore, it is 
important that some defensins act to control these responses via a negative 
feedback mechanism30. 
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1.5 Vitamin D, AMPs and respiratory tract infection 
The presence of vitamin D receptors (VDRs) in most cells of the immune 
system suggests that vitamin D plays a role in the regulation of immunity2, both 
innate and adaptive12. Of particular relevance to this study, is the involvement of 
vitamin D in the expression of human cathelicidin (hCAP-18/LL-37) and 
β defensin-2 (hBD-2) in the respiratory tract.  
The respiratory immune system is extremely important for the protection 
of the large surface area exposed to inhaled environmental threats, such as 
microorganisms. In addition to the physical defences provided by cilia and mucus, 
antimicrobial peptides are thought to play a vital role33; 34; 35. 
The epithelial cells of the lungs and respiratory tract have been shown to 
produce both LL-37 and hBD-2, and their expression is upregulated in response to 
microbial invaders34; 35; 36. Recognition of these foreign organisms is thought to 
occur via Toll-like receptors (TLRs), which can then regulate the expression of a 
variety of genes, including antimicrobial peptides and cytokines34. Evidence of 
AMP induction in response to respiratory infection has been indicated in a number 
of studies, where peptide levels are significantly higher in patients suffering from, 
for example, pneumonia36 or cystic fibrosis (CF), than in healthy controls. One 
proposed explanation for the frequent infection observed in CF patients is the high 
salt concentration of the airway surface fluid, which is known to drastically 
reduce the bactericidal activity of antimicrobial peptides34; 35. 
The enzymes responsible for the conversion of vitamin D to its active form 
are not only found in the liver and kidneys, but also in various cells of the immune 
system (e.g. macrophages)4. It has been suggested that vitamin D plays a role in 
the regulation of AMP expression, and that deficiencies can lead to an impaired 
immune response33.  
Microbial stimulation of TLR-2 induces expression of CYP27B1 – the 
enzyme responsible for converting the storage form of vitamin D (25D) into the 
active metabolite (1,25D), and increasing the amount available for binding to the 
receptor7; 37; 38. Once bound to the VDR, vitamin D exerts its biological effects on 
target genes by binding to response elements (VDREs) in their promoter regions. 
These elements have been identified in the hCAP-18 gene (CAMP), and it has 
been shown that 1,25D can increase CAMP expression39. Wang et al.40 showed 
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that VDREs are also present in hBD-2 genes, but noted that induction by 1,25D is 
much more significant for CAMP. In addition, Liu et al.38 showed that the lower 
vitamin D levels often found in the serum of individuals with more melanin (e.g. 
African-Americans) did not allow the same level of TLR-mediated cathelicidin 
induction as Caucasian serum. However, they also demonstrated that similar 
levels of induction could be obtained in the African-American subjects after 
supplementation with vitamin D. 
In 1981, Hope-Simpson suggested that the seasonality of influenza was 
associated with some aspect of solar radiation33, and since then, many studies 
have investigated the relationship between low vitamin D levels and increased 
incidence of respiratory infection. For example, Muhe et al.14 found a strong 
correlation between cases of rickets and pneumonia in Ethiopian children, and 
Laaksi et al.41 found that Finnish military recruits with lower vitamin D levels had 
more frequent absenteeism due to respiratory infection.  
As AMP expression is involved in protecting against respiratory infection, 
and appears to be influenced by vitamin D, it seems logical to infer that 
individuals with low vitamin D levels will also have low AMP expression and, as 
a result of this impaired immune response, would be expected to suffer from more 
severe infections. A recent study on haemodialysis patients used this logic to 
investigate the relationship between vitamin D, hCAP-18 and mortality due to 
infection. The results showed that while hCAP-18 levels were strongly associated 
with mortality, their correlation with vitamin D was not statistically significant39.  
This study will focus on the relationship between AMPs and vitamin D in 
community acquired pneumonia (CAP) and exacerbations of chronic obstructive 
pulmonary disease (COPD) – respiratory conditions thought to involve microbial 
infection. Although smoking is a known risk factor for COPD, a full 
understanding of the basis of the disease is not yet known12. Exacerbations of this 
condition may be caused by bacterial infection, or by viral infections (particularly 
rhinovirus) – which have been implicated in up to a third of cases42. This study 
may help identify whether vitamin D has potential as a therapeutic agent for the 
reduction of infection and inflammation in these conditions12. 
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1.6 Vitamin D binding protein 
Vitamin D binding protein (DBP) was initially identified as group-specific 
component (Gc-globulin), and is found in plasma at concentrations of 300-
600 µg/mL43. It belongs to the albumin superfamily of genes, which forms a 
cluster on chromosome 4, and also contains albumin, afamin and α-fetoprotein. 
The 51–59 kDa polypeptide is made up of 458 amino acids, and has two binding 
regions, which are responsible for its two main biological functions. The first of 
these is the vitamin D binding domain, where vitamin D and its metabolites are 
bound for transport throughout the circulation43; 44; 45. DBP-bound metabolites 
have a longer half-life than the free forms, meaning the binding protein can delay 
the removal of the vitamin from the body, and thereby increase its period of 
activity43.  
There is a large excess of DBP in comparison to ligand however, and it 
has been suggested that this is required for the other major role of DBP – actin 
scavenging via the actin binding domian43. Cell death triggers the release of 
globular actin (G-actin) into the circulation, where it can polymerise to form 
filamentous actin (F-actin). These filaments can obstruct blood flow and cause 
organ failure. To prevent this, the gelsolin protein breaks F-actin into G-actin, 
which is then sequestered by DBP43; 44; 45.  
Several other roles of DBP have also been suggested, including acting as a 
co-chemotactic factor, and a macrophage-activating factor (MAF)43; 44; 45. 
 
1.6.1 Polymorphisms 
 The DBP is highly polymorphic, with three common alleles (Gc-1F, Gc-
1S and Gc-2) and more than 120 rare alleles43; 45. Some of these rare 
polymorphisms may reach higher levels in specific populations (e.g. Australian 
Aborigine and Chippewa Indians have a number of variants that are rare in 
Caucasian populations)46. The three common alleles arise as a result of single 
nucleotide polymorphisms (SNPs) which cause single amino acid substitutions 
(Table 1.1)44. This gives rise to six common DBP phenotypes: Gc1F-1F, Gc1F-1S, 
Gc1F-2, Gc1S-1S, Gc1S-2, and Gc2-245. 
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Table 1.1 – Amino acid residues that produce Gc-globulin isoforms, modified 
from Christiansen et al.44 
 
Isoform 
Amino acid 
residue at 
position 416 
Amino acid 
residue at 
position 420 
Theoretical 
molecular 
weight (Da) 
Gc-1F D T 51188 
Gc-1S E T 51202 
Gc-2 D K 51215 
 
The frequency of each allele varies with geographical region43; 46, and it 
has been suggested that there is a correlation between allele frequency and degree 
of skin pigmentation. For example, Gc-1F has a higher efficiency of vitamin D 
transport, and binds it with more affinity, and the frequency of this variant is 
highest in dark-skinned populations (where UV-mediated vitamin D synthesis is 
lower)43. 
Fu et al.47 demonstrated that mean vitamin D (25D) levels vary with 
genotype at position 420 (T436K SNP), with lowest levels present in K allele 
homozygotes (KK). They also showed that individuals respond differently to 
vitamin D supplementation, depending on their DBP genotype. In this case, KK 
homozygotes showed the most significant increase in plasma concentration after 
supplementation, followed by TK, and finally TT individuals. On the other hand, 
the presence of D versus E alleles at position 416 (D432E SNP) did not show a 
significant correlation with baseline 25D or supplementation effect. 
 
1.6.2 DBP and COPD 
Many studies have focussed on the clinical significance of the DBP 
isoforms43; 45, and some have found a relationship between genotype and risk of 
developing chronic obstructive pulmonary disease (COPD)43; 48; 49; 50.  
Airway inflammation and obstruction of airflow are the main 
characteristics of this respiratory disease, the chief risk factor for which is 
cigarette smoking. However, the observation that the majority of smokers do not 
develop COPD48; 50, and that it shows familial associations, led to the suggestion 
that there was a genetic component to the disease49; 50. 
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A number of groups have investigated the relationship between the three 
common DBP polymorphisms, and risk of COPD development. Both Ishii et al.48 
and Ito et al.49 showed that the frequency of the Gc-1F allele was higher in COPD 
patients than in healthy controls, and that homozygous 1F-1F genotypes appear to 
increase the risk of disease development further. It is important to note however, 
that the frequencies of these alleles vary with different populations, and both 
studies were carried out using Japanese subjects. Schellenberg et al.50 could not 
confirm this finding in a study using Caucasian participants, but attributed this to 
the low frequency of the Gc-1F allele in this population giving an insufficient 
number of individuals for significance. However, this group did find that the 
frequency of the homozygous Gc2-2 genotype was significantly lower in the 
COPD group than the controls, suggesting it may have a protective effect. The 
same could not be said for the heterozygotes, however. 
Although the reason behind these differences in COPD risk between DBP 
variants has not yet been determined, it is thought to be associated with the role of 
DBP as a macrophage-activating factor (MAF). For conversion to MAF, DBP 
undergoes deglycosylation. The sugar side chains that are removed in this process 
are the same in Gc-1F and Gc-1S, but absent in Gc-2. This means that Gc-2 
cannot be converted, and less MAF is produced in individuals with that genotype. 
This means that these individuals may have a reduced inflammatory response, and 
therefore less lung damage49; 50.
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2. Experimental 
Note – See Appendix 6.1 for buffer and solution recipes, grouped by method. 
 
2.1 Determination of vitamin D status and infection severity 
 This study gained approval from the Northern Y (NTY/08/05/045) and 
University of Waikato Human Research (Protocol #93) ethics committees. 
Members of the Department of Respiratory Medicine at Waikato Hospital 
carried out the measurements of vitamin D status and infection severity. Patients 
admitted to the department with community acquired pneumonia (CAP) or acute 
exacerbations of chronic obstructive pulmonary disease (COPD) were invited to 
participate in the study, and written consent was obtained from those who 
accepted.  
 Blood samples were taken from these patients within 24 hours of 
admission, and the concentration of vitamin D determined by competitive 
electrochemiluminescence immunoassay (Elecsys, Roche Diagnostics). Measures 
of co-morbidities and infection severity were also performed, using the Charlson 
Index score and the CURB65 score, respectively51. 
 
2.2 ELISA 
2.2.1 Quantification of β defensin-2 in human plasma  
 The plasma concentration of human β defensin-2 (hBD-2) in each sample 
was determined using the Human BD-2 ELISA Development Kit (PeproTech Inc, 
900-K172), according to the instructions of the manufacturer. 
Reconstituted capture antibody was diluted 1:400 in phosphate buffered 
saline (PBS) to a concentration of 0.25 µg/mL, and 100 µL was added to each 
well of a 96-well plate. The plate was covered in foil and incubated overnight at 
room temperature, then washed four times using 200 µL of wash buffer (0.05% 
Tween-20 in PBS) per well. Block buffer (1% BSA in PBS) was added at 200 µL 
per well, and the was plate incubated at room temperature for at least 1 h, before 
being washed in PBS-Tween, as above. Human BD-2 standard was serially 
diluted with diluent (0.05% Tween-20, 0.1% BSA in PBS) to give standard 
concentrations of 1000, 100, 10 and 1 pg/mL, and 100 µL of each was added to 
the plate in duplicate. A blank (diluent only) and the plasma samples were also 
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added in duplicate, at 100 µL per well. The plate was incubated overnight at 4 °C, 
and washed four times. Reconstituted detection antibody was diluted 1:200 (in 
diluent) to 0.5 µg/mL, and 100µL added to each well. After incubating at room 
temperature for 2 h, and washing the wells four times, 100 µL of avidin-HRP 
conjugate (diluted 1:2000 in diluent) was added per well. The plate was washed 
again before adding 100 µL of ABTS (2,2’-Azino-Bis(3-Ethlybenzthiazoline-6-
Sulfonic Acid); Sigma, A 3219) substrate to each well. Colour development was 
monitored at 5 min intervals for 30 min using an ELISA plate reader (FLUOStar 
Optima) at 405 nm, with a wavelength correction of 690 nm. A standard curve 
was generated to allow determination of sample concentrations of hBD-2 (see 
Appendix 6.3 for an example calculation). 
 
2.2.2 Quantification of LL-37 in human plasma 
 The LL-37 concentration in each plasma sample was determined using the 
Human LL-37 ELISA Test Kit (Hycult Biotechnology, HK321), according to the 
instructions of the manufacturer. 
 Briefly, reagents were reconstituted as instructed, and samples brought to 
room temperature. The LL-37 standard was serially diluted in wash/dilution 
buffer to give a concentration range of 100, 22.3, 11.1, 3.7, 1.2, 0.4 and 0.1 ng/mL. 
A blank of 0 ng/mL was also prepared as a control. The blank and standards were 
added to the plate in duplicate, at 100 µL per well, as were the plasma samples 
(diluted 1:20 in wash/dilution buffer). The plate was incubated at room 
temperature for 1 h, and washed four times with 200 µL of wash/dilution buffer 
per well. Tracer was added at 100 µL per well, and incubated for 1 h at room 
temperature. After washing as above, 100 µL of streptavidin-peroxidase conjugate 
was added to each well, incubated for 1 h at room temperature and washed four 
times. TMB (tetramethylbenzidine) substrate was added (100 µL per well) and the 
plate incubated for 20-30 min in the dark. The reaction was stopped by adding 
100 µL of stop solution per well, and the absorbance was measured at 450 nm 
using a plate reader (FLUOStar Optima). 
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2.3 Purification of plasma peptides 
2.3.1 Albumin removal and TCA precipitation 
The plasma purification protocols of Colantonio et al.52 and Jiang et al.53 
were combined to improve detection of small peptides, as suggested by 
McKenzie54.  
To each plasma sample, 1 M sodium chloride (NaCl) was added to give a 
final concentration of 0.1 M, and the samples were incubated at 4 °C on a rotating 
mixer for 1 h. Cold ethanol was added to give a final concentration of 42%, and 
the samples were centrifuged for 45 min at 13,000 rpm and 4 °C. The pellet 
(pellet 1) was retained, and the pH of the supernatant lowered to 5.7 with 0.8 M 
sodium acetate (NaAc). The supernatants were incubated at 4 °C for 1 h, and 
centrifuged for 45 min at a speed of 16,000 g, to produce pellet 2. 
Pellets 1 and 2 of each sample were combined and resuspended in 200 µL 
of PBS and 40 µL of 60% trichloroacetic acid (TCA). The samples were 
incubated overnight at -20 °C, and centrifuged for 30 min at 10,000 g and 4 °C. 
The supernatant was discarded and 300 µL of cold acetone added to wash each 
pellet. The samples were incubated on ice for 15 min, and centrifuged as above. 
Finally, the acetone was removed, and the pellet left to air dry. 
To run the samples on a gel, pellets were resuspended in water and gel loading 
buffer (GLB), heated to 95 °C for 5 min, and briefly centrifuged so the 
supernatant could be loaded. 
 
2.3.2 TCA precipitation 
 To perform the TCA precipitation step only, PBS was added directly to 
12.3 µL of plasma to give a final volume of 200 µL, before proceeding to the TCA 
step, as described above.  
 
2.3.3 Acetic acid and methanol precipitation 
Cole and Ganz 55 suggest the use of acetic acid and methanol to precipitate 
out unwanted material, but leave antimicrobial peptides in the supernatant fraction. 
A method employed by Tang et al.56 to isolate α-defensins from leukocytes also 
used this idea, so was tested to determine whether it was as effective in the 
purification of other antimicrobial peptides from plasma.  
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To 100 µL of plasma, 900 µL of 80:10 methanol:acetic acid was added and 
stirred for 18 h, then centrifuged. Supernatants were dried in a SpeedVac and 
resuspended in 1 mL of 80:20 methanol:water. Samples were stirred for 6 h, 
centrifuged and dried as above, and acidified by adding 0.1 mL 5% acetic acid. 
The supernatant obtained after a final centrifugation step was retained and mixed 
with gel loading buffer for electrophoresis. 
 
2.3.4 C-18 Filter Tips 
Eppendorf PerfectPure C-18 pipette tips were also used in some cases, to 
further process the supernatant before analysis. These tips act to desalt the sample, 
and have a pore size that makes them selective for peptides with molecular 
weights of less than 15 kDa. The tips were applied to a pipette set at 10 µL, and 
pre-wet solution (50% acetonitrile (ACN), 0.1% trifluoroacetic acid (TFA)) was 
taken up and discarded several times, without allowing air to enter. This was 
repeated using equilibration/wash solution (0.1% TFA), before aspirating and 
expelling the sample up to ten times, followed by equilibration/wash solution up 
to five times. Elution solution (75% ACN, 0.1% TFA) was aspirated at least three 
times, before dispensing into a clean tube. This eluate was either mixed with gel 
loading buffer for electrophoresis, or with matrix on a target for mass 
spectrometry (MS). 
 
2.4 Gel Electrophoresis  
2.4.1 Tris-Tricine SDS-PAGE  
Tris-Tricine gels are used in cases where the separation of small proteins 
(<30 kDa) is required. These gels were prepared according to the method 
described by Schägger57 (Table 2.1), using a solution of acrylamide:N,N'-
methylenebisacrylamide at a concentration of 49.5%, with 3% or 6% cross-linking 
(AB-3 or AB-6, respectively). Using higher percentage gels with a greater degree 
of cross-linking is suggested to improve the separation of small peptides. Other 
suggestions include the addition of urea or the use of spacer gels between the 
stacking and separating layers57. 
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Table 2.1 – Recipe for large Tris-Tricine gel 
 
Stacking 
Gel 
Separating Gel 
STOCK SOLUTION 
4% 10% 12.5% 16% 16%/6
M urea 
AB-3 or AB-6 (mL) 1 6 7.6 10 10 
3x Gel Buffer (mL) 3 10 10 10 10 
Glycerol (g) - 3 3 3 - 
Urea (g) - - - - 10.8 
Add water to final volume 
(mL) 
12 30 30 30 30 
10% (w/v) APS (µL) 90 150 150 100 100 
TEMED (µL) 9 15 15 10 10 
 
To prepare each gel, the glass plates were cleaned with ethanol and 
acetone, and assembled. The desired gel concentration was determined, and the 
corresponding volumes of AB-3 (or AB-6), gel buffer, water, and glycerol were 
added to a flask. To prevent polymerization occurring too early, tetramethyl-
ethylenediamine (TEMED) and 10% (w/v) ammonium persulphate (APS) were 
added last. Immediately after APS addition, the solution was mixed, taken up in a 
syringe, and poured between the assembled plates. A layer of 2-butanol was added 
to level the top of the gel, and prevent it from drying out. Once the separating gel 
had set, the butanol was removed and the stacking gel prepared and applied on top. 
The gel comb was carefully inserted into this layer, which was then left to 
polymerize. 
To run the gel, the plates were secured to the electrophoresis apparatus, 
and cathode and anode buffer were placed in the upper and lower buffer chambers 
respectively. The gel was pre-electrophoresed at 18 mA for 15 min, before 
loading the samples, standards, and molecular weight ladder (Bio-Rad 
Polypeptide SDS-PAGE Molecular Weight Standards, 161-0326).  
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The current was maintained at this level until the gel front progressed past 
the stacker and into the separating gel, at which point it was increased to about 
45 mA, until the gel front reached the bottom. 
 
2.4.2 Laemmli SDS-PAGE 
Laemmli gels are more suitable for larger proteins (>30 kDa)57, and the 
size of the protein of interest will determine the separating gel percentage to be 
used. Basically, separation of smaller proteins requires a more concentrated gel.  
The gels were prepared using the method described by Coligan et al.58 
(Table 2.2), and concentrations of 7-12% were used.  
 
Table 2.2 – Recipe for large Laemmli Gel 
 
Separating Gel 
STOCK SOLUTION 
Stacking 
Gel 7% 7.5% 10% 12% 
30% acrylamide/0.8% bis 
(mL) 
 
0.65 3.50 3.75 5.00 6.00 
4 x Tris-Cl/SDS pH 8.8 (mL) - 3.75 3.75 3.75 3.75 
4x Tris-Cl/SDS pH 6.8 (mL) 1.25 - - - - 
Water (mL) 3.05 7.75 7.50 6.25 5.25 
10 % (w/v) APS (µL) 25 50 50 50 50 
TEMED (µL) 5 10 10 10 10 
 
The same assembly and electrophoresis conditions used for Tris-Tricine 
gels were employed. However, for the Laemmli gels, both buffer chambers were 
filled with 1x SDS electrophoresis buffer, and a different molecular weight ladder 
(Bio-Rad Precision Plus Protein Standards (Dual Colour), 161-0374) was used. 
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2.5 Gel Staining 
2.5.1 Blue-Silver 
Gels were fixed in 50% methanol, 2% phosphoric acid for 30-40 min, 
stained overnight in blue micellar solution, and destained in 5% methanol. Bands 
of interest were excised from the gel for further analysis (see section 2.6). 
 
2.5.2 Silver 
i. Basic Silver Staining 
Gels were fixed for 15 min in 100 mL fixing solution, and washed in 
100 mL 30% ethanol for 2 min. Gels were then sensitized by soaking in 100 mL 
0.02% sodium thiosulfate for 1 min. Excess sensitizer was removed by washing 
gels twice in Milli-Q water (10 seconds each), before staining for 10 min. After 
repeating the Milli-Q washes, gels were soaked in developer until bands appeared. 
Once visible, the reaction was stopped by removing the developer and adding 
100 mL of 10% acetic acid. 
 
Note: When silver staining a gel that had already been stained with blue-silver, 
excess Coomassie was removed by washing in Milli-Q, then gels were taken 
straight to the sensitizing step of the basic silver staining protocol (i.e. 1 min in 
0.02% sodium thiosulfate). 
 
ii. Alternative Silver Staining Protocols 
The basic silver staining method is not compatible with matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry. For 
this reason, the alternate protocols used by He et al.59 and Yan et al.60 were trialled 
in an attempt to improve detection of small, low abundance peptides, while 
mainitaining MS-compatibility. 
 
a) He Silver Staining 
Gels were fixed overnight in a 30% ethanol, 10% acetic acid solution, and 
soaked in sensitizer for 30 min. After three 5 min water washes, gels were stained 
for 40 min, and incubated in developer for 15 min. This reaction was stopped by 
adding 1.46 % EDTA, followed by three 5 min water washes.  
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b) Yan Silver Staining 
Gels were incubated twice in fixing solution, for 15 min per wash, and 
sensitized for 30 min. After three 5 min washes in Milli-Q, gels were stained for 
20 min, and washed another two times in water for 1 min each. Bands were 
visualised by incubating in developer, before stopping the reaction by washing 
with 1.46% EDTA for 10 min.  
 
2.6 In-gel digestion (for Blue-Silver stained gels) 
Bands of interest in blue-silver stained gels were either cut out using a 
scalpel, or extracted as a plug using a glass pipette. Excised bands were destained 
overnight in 1:1 acetonitrile:25 mM ammonium carbonate, and then washed for 
15 min in the same solution, followed by 15 min in ACN.  After removal of this 
solution, the gel plugs were dried (air or SpeedVac), and 10 µL of Promega 
Trypsin Gold (diluted 1:200 in 25 mM ammonium carbonate) was added. The 
samples were incubated at 4 °C for 1 h to allow the trypsin solution to rehydrate 
the gel pieces. Excess trypsin was removed and samples were incubated at 37 °C 
for 4-6 h. To prevent evaporation during this time, parafilm was wrapped around 
the top of each tube. Finally, samples were incubated overnight at 4 °C in 10 µL 
of 20% ACN, 0.1% TFA. This solution acted to aid diffusion of proteins out of 
the gel pieces, and helps ionize the peptides for mass spectrometric analysis. 
 
2.7 MALDI-TOF mass spectrometry 
All mass spectrometry was performed on an AutoflexTM II MALDI-TOF 
mass spectrometer (Bruker Daltonics) using FlexControlTM software, and spectra 
were analysed using FlexAnalysisTM and BioTools (Bruker Daltonics). 
 
2.7.1 Sample Preparation and loading 
i. Dried Droplet 
For a dried droplet preparation, 0.5 µL of matrix was added to the target 
plate followed by an equal volume of sample. The two were pipetted up and down 
several times to mix, then left to dry.  
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Dried droplet can be used on AnchorChip, aluminium or steel targets, but 
the latter two allow the sample to be dispersed over a larger area, which may be 
better for detection. 
 
ii. Thin Layer 
A saturated solution of α-Cyano-4-hydroxycinnamic acid (CHCA) matrix 
in acetone was prepared and 10 µL dragged across the target. The acetone 
evaporated, leaving a thin layer of matrix on the hydrophilic centres of the 
AnchorChip target plate. To each of these centres, 0.5 µL sample was applied and 
left to dry. 
	  
iii. Washing 
A washing step can be included in both dried droplet and thin layer 
methods. The wash solution used was a 9:1 mixture of 0.1% trifluoroacetic acid 
(TFA):100 mM ammonium phosphate (NH4H2PO4). This is a volatile solution so 
evaporates off in the vacuum, while acting as a buffer to remove some of the salt 
and thereby give a better signal. However, washing can also remove some of the 
sample, particularly in dried droplet preparations.	   
To perform a wash, 5 µL of the solution was applied to each spot of 
sample and matrix, and then removed after approximately 5 seconds.  
 
2.7.2 Calibration  
A peptide calibration standard (Bruker Daltonics) was mixed with matrix 
and applied to the MALDI target plate in the same area as the sample spots. 
Spectra collected from these standard spots were used to calibrate the instrument, 
before analysing the samples. 
 
2.7.3 Lysozyme Gels 
A range of concentrations of lysozyme were run on small 16% Tris-
Tricine gels, to determine the cut-off concentration for detection by blue-silver 
staining. The bands at the lowest detectable concentration were cut out of the gel 
as whole bands or single plugs, and a comparison of the dried droplet, thin layer, 
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and washing procedures was carried out. To allow optimum performance of each 
technique, the dried droplet preparation was performed on a steel MALDI target, 
and a 600 µm AnchorChip target was used for thin layer. 
 
2.7.4 Plasma Screening 
Pellets from the albumin removal/TCA precipitation method were 
resuspended in 40 µL Milli-Q water, and centrifuged. The supernatants were 
either applied directly to the MALDI target plate, or were filtered with C-18 tips 
before loading. The samples were mixed 1:1 with matrix (5 µL each) on an 
aluminium target, using the dried droplet method. The matrix used was 2,5-
dihydroxybenzoic acid with 10% 5-methoxysalicylic acid (super DHB (sDHB)), 
which had been made up in 40 µL 1:2 ACN:0.1% TFA, to give a saturated 
solution. 
Human beta defensin-2 (hBD2) and cathelicidin (LL-37) standards from 
their respective ELISA kits were also filtered with C-18 tips, and mixed 1:1 with 
sDHB matrix on the target. 
Sample and standard spectra were collected using a linear detector and 
high laser power method. 
 
2.7.5 Peptide Fingerprinting 
To perform MALDI-TOF on samples excised from gels and trypsin-
digested, α-Cyano-4-hydroxycinnamic acid (CHCA) matrix was used. This is a 
better matrix for the analysis of small peptides because it requires less energy to 
ionise. A saturated solution of CHCA was made up in 40 µL 2:1 ACN:0.1% TFA, 
before mixing 1:1 (0.5 µL each) with samples on the target. In most cases, the 
target used was a 600 µm AnchorChip plate, as this allowed for tandem mass 
spectrometry.  
Analysis of peptide digests was carried out using the reflector detection 
method. This adjusts for the energy spread of ions, and gives a more resolved 
peak, which is important for peptide identification. To perform a database search, 
the Mascot program from Matrix science was used, with the following search 
parameters: Chordata, trypsin digestion, up to one missed cleavage, a mass 
tolerance of no more than 200 ppm, and monoisotopic. The National Center for 
Biotechnology Information nonredundant (NCBInr) database was used, and 
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protein scores of >73 (as calculated by Mascot) were classed as being significant 
database hits (p<0.05). 
 
2.7.6 Tandem Mass Spectrometry 
Tandem mass spectrometry, using the LIFTTM method, enables the 
analysis of the amino acid sequence of a particular peak of interest from an MS 
spectrum. The parent ion is fragmented further to (ideally) give single amino acid-
length fragments, the spectrum of which can help to ascertain the sequence of that 
parent ion. This may help in the determination of the identity and possibly even 
the sequence of the peptide. 
 
2.8 Identification of DBP polymorphisms 
2.8.1 Extraction of DNA from Saline Mouthwash 
After gaining approval from the University of Waikato Human Research 
ethics committee (Protocol #95), volunteers were asked to carry out a 0.9% saline 
mouthwash and dispel the liquid into a 50 mL tube. These were centrifuged at 
2,500 rpm for 15 min and the supernatant discarded. To each pellet, 350 µL lysis 
solution was added and mixed, then transferred to a 1.7 mL eppendorf tube. The 
samples were heated (while shaking) at 55 °C, for 10 min. An equal volume of 
5 M lithium chloride (to salt out the protein), and 750 µL of chloroform were 
added, and the tubes shaken and placed on a rotating mixer for 30 min. After 
centrifuging for 10 min, the top layer was transferred to a new tube, and the rest 
discarded. The DNA was precipitated with an equal volume of isopropyl alcohol 
for 30-60 min, and centrifuged for 20 min. The liquid was tipped off, and the 
DNA pellet washed with 1 mL 70% ethanol. After removal of the ethanol, pellets 
were resuspended in 50 µL TE buffer.  
 
2.8.2 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction (PCR) was performed on the extracted DNA 
samples to amplify the vitamin D binding protein (DBP) gene, and determine the 
polymorphisms present. This was carried out using the primers and PCR 
conditions of Fu et al.47 A 50 µL reaction was prepared for each sample. This 
included master mix, i-StarTaqTM polymerase, and three primers – 0.5 µM of 
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common forward, 0.5 µM of wild-type reverse, and 0.2 µM of mutant reverse (see 
Appendix 6.2 for sequences). Excluding the negative control, 2.5 µL DNA was 
added to each tube. The PCR conditions were set at 95 °C for 2 min, followed by 
35 cycles of 95 °C for 20 sec, 58 °C for 20 sec, and 72 °C for 20 sec. At the end of 
the last cycle, an additional step of 68 °C for 5 min was included. 
 The PCR products were run on 2% agarose/1xTAE gels containing 
ethidium bromide, with 6x loading buffer and 1x TAE running buffer. The 
Invitrogen 100 bp ladder was used for all gels to allow the approximate size of 
bands to be determined when visualised under UV light. 
 
2.8.3 Restriction Enzyme Digestion 
To determine the D432E genotype, 10 µL of the PCR amplified mixture 
was incubated overnight at 37 °C, with 1 µL of the restriction enzyme HaeIII. The 
restriction enzyme digests were then run on 2% agarose/1x TAE gels, as above.  
 
2.8.4 Touchdown Protocol 
 A different PCR protocol was also trialled, with conditions: 95 °C for 
2 min; 10 cycles of 20 sec at 95 °C and 20 sec at 62.5 °C (-0.5 °C per cycle); 35 
cycles of 20 sec at 95 °C, 20 sec at 58 °C and 72 °C for 20 sec; and finally 68 °C 
for 5 min. In this case, mutant and wild type reverse primers were run as separate 
reactions. 
 
2.8.5 Purification of PCR products for sequencing (PEG precipitation) 
 Polymerase chain reaction (PCR)-amplified products were pipetted into 
1.7 mL Eppendorf tubes, and an equal volume of polyethylene glycol (PEG) was 
added. After leaving to precipitate for at least 10 min, the mixture was centrifuged 
and the liquid poured off. The pellet was washed by adding 1 mL 100% ethanol 
and centrifuging for 5 min, before tipping off the liquid and repeating with 70% 
ethanol. After removing all the liquid, 10 µL Milli-Q water was added, and the 
tube vortexed to resuspend the pellet. The DNA concentration was measured by 
NanoDrop, and submitted for sequencing along with the common forward primer, 
at a concentration of 5 pmol/µL.
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3. Results and Discussion 
3.1 Determination of vitamin D status and infection severity 
 Vitamin D deficiency is defined as a serum concentration of less than 
50 nmol/L, and 49% of all the study patients fell within this category. Of these, 
35% (i.e. 17% of all patients) were severely deficient, with levels of <30 nmol/L.  
The CURB65 score takes into account a number of clinical factors (e.g. 
blood pressure, respiration rate), and uses them to assign a number (between 0 
and 5) to patients with pneumonia or exacerbations of COPD. This number 
predicts the risk of 30-day mortality, and therefore acts as a marker for infection 
severity, with lower scores representing milder infections and reduced chance of 
death.  
Table 3.1 shows the vitamin D and CURB65 score statistics for all the 
study patients, and for the CAP and COPD groups individually. The average 
CURB65 score overall was 2, and was higher among patients who died within 30 
days (average = 3) than those who did not (average = 2).  
 
Table 3.1 – Vitamin D status, CURB65 and 30-day mortality statistics of 
patients with respiratory tract infection 
 
 
All patients 
n = 185 
CAP patients 
n = 112 
COPD patients 
n = 73 
Vitamin D status    
Severely deficient 
(<30 nmol/L) 
17.30% 15.18% 20.55% 
Deficient (30-49 nmol/L) 31.89% 28.57% 36.99% 
Sufficient (≥50 nmol/L) 50.81% 56.25% 42.47% 
CURB65 score    
0-1 30.27% 28.57% 32.88% 
2-3 55.14% 52.68% 58.90% 
4-5 14.59% 18.75% 8.22% 
30-day mortality    
Number of patient deaths 
within 30 days 
9.73% 8.04% 12.33% 
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As shown in Figure 3.1, an assessment of the average vitamin D 
concentration at each CURB65 score did not reveal any significant trend, but it 
did highlight the fact that patients with COPD had lower average vitamin D levels 
across all scores, and no COPD patients reached the highest risk level (CURB65 
score of 5). 
 
Figure 3.1 – Comparison of average vitamin D concentration and CURB65 
 
However, a comparison of vitamin D status and mortality did reveal a 
relationship. Whether pneumonia and COPD were analysed individually or 
together, mortality was substantially higher in patients with severe deficiency. In 
addition, data collected from pneumonia patients follows a clear trend, with 
highest mortality rates in patients with severe deficiency (29.41%), followed by 
those with a mild deficiency (6.25%), and lowest rates in those with adequate 
levels of vitamin D (3.17%), as shown in Figure 3.2. This trend can also be seen 
when assessing the two respiratory infections together, but not when analysing 
COPD data alone, as patients with adequate amounts of vitamin D had higher 
rates of mortality (12.90%) than those classed as mildly deficient (7.41%).  
Together, these results indicate that the serum 25D concentration is not 
directly related to CURB65 in pneumonia or exacerbations of COPD, nor is it 
predictive of mortality in COPD. These conclusions were confirmed after log-
transformation of the data and logistic regression analysis, which showed that the 
CURB65 score is a predictor of mortality (p=0.001), while 25D (grouped 
according to status) is significant in pneumonia (p=0.002), but not in COPD 
(p=0.489).  
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Figure 3.2 – Relationship between 30-day mortality and vitamin D status 
 
3.2 Plasma hBD-2 and LL-37 levels by ELISA 
Indirect ELISA was used to determine the concentrations of LL-37 and 
hBD-2 in the plasma of patients with pneumonia and acute exacerbations of 
COPD (see Appendix 6.3 for full results). The mean and median were higher in 
pneumonia for both antimicrobial peptides, but COPD patients exhibited a wider 
concentration range (Table 3.2). 
 
Table 3.2 – Basic statistics for LL-37 and hBD-2 as determined by ELISA 
 
 LL-37 concentration 
(ng/mL) 
hBD-2 concentration 
(pg/mL) 
 CAP COPD CAP COPD 
Mean 80.41 
 
65.58 
 
421.37 
 
342.87 
 
Median 68.46 
 
59.99 
 
261.55 
 
188.38 
 
Range 13.16 - 
263.49 
10.26 - 
341.25 
13.96 - 
1733.62 
15.31 - 
2469.39 
 
These ELISA results were divided into tertiles and compared to 30-day 
mortality, to determine whether any correlation existed (Figure 3.3 a-c). 
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Figure 3.3 – Relationship between percentage 30-day mortality and 
concentration of LL-37 and hBD-2 in a) Both CAP and COPD, b) CAP only, 
and c) COPD only 
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3.3 Discussion of relationships between hBD-2, LL-37,  
vitamin D and 30-day mortality 
The presence of vitamin D response elements (VDREs) in the promoter 
regions of both LL-37 and hBD-2 genes led to the hypothesis that patients with 
low levels of vitamin D would have correspondingly low concentrations of these 
antimicrobial peptides. Spearman’s non-parametric correlations were used to 
determine whether any relationships existed between these variables, as all three 
showed skewed distributions. 
No significant correlations where found between 25D and LL-37 
(p=0.549), 25D and hBD-2 (p=0.990), or LL-37 and hBD-2 (p=0.405), and this 
lack of significance remained when analysing pneumonia and COPD individually.  
Therefore, although previous studies have shown the ability of 1,25D to 
induce both LL-37 and hBD-2, the present findings do not support the hypothesis 
of a direct relationship between vitamin D status and antimicrobial peptide level, 
and indicates that other factors must influence the expression levels of these 
VDRE-containing genes.  
Any factor involved in the uptake of 25D into target cells, the conversion 
of 25D to 1,25D, the levels of VDR, or the formation and binding of the VDR-
RXR complex to VDREs, could conceivably affect the expression of such target 
genes. For example, as the binding of 1,25D to the receptor is the first step in the 
vitamin D-mediated gene expression pathway, VDR upregulation (e.g. by 1,25D 
or protein kinase A) or downregulation (e.g. by protein kinase C) would influence 
the capacity for regulation of downstream targets. In addition, transcription factors 
(TFs) or coregulatory elements such as NF-κB are required to bind to the VDR-
RXR complexes at VDRE sites, in order for the target genes to be expressed. 
Therefore, the availability of these elements could also influence the levels of 
vitamin D-regulated gene products61. 
Another possibility for the lack of association between antimicrobial 
peptide concentration and vitamin D status may be that the serum 25D level is 
used to determine the status, while 1,25D is the active form that interacts with the 
VDR to mediate changes in gene expression. Therefore, a relationship may exist 
between 1,25D and these AMPs that is not seen when using standard clinical 
measures. 
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 Further statistical analyses were carried out after log transformation of the 
data. This made the data assume a more normal distribution, and thereby allowed 
parametric tests to be used. 
 As discussed in section 3.1, the relationship between plasma 25D status 
and 30-day mortality was significant only in pneumonia. Using the data from both 
respiratory infections together, the relationship between 25D and 30-day mortality 
reaches a higher significance (p=0.001 compared to 0.006) if vitamin D is 
analysed as low (<30 nmol/L) or not (≥30 nmol/L), rather than as a continuous 
variable (i.e. by status – severely deficient, deficient, or sufficient). In addition, 
logistic regression showed that the relationship between 30-day mortality and low 
vitamin D remained after adjusting for sex, age, and diagnosis (pneumonia or 
COPD). Based on these findings, “low vitamin D” was used as the 25D variable 
in further analyses.  
 Figure 3.3 (a-c) suggests that lower plasma LL-37 concentrations are 
associated with a higher risk of 30-day mortality, whether analysing pneumonia 
and COPD together, or individually. Logistic regression confirmed this finding, 
and showed that plasma LL-37 remains a strong predictor of 30-day mortality 
after adjusting for age, sex, diagnosis, CURB65 score, Charlson index, hBD-2 
level, and low vitamin D. Individual analysis however, showed that the 
relationship between LL-37 and 30-day mortality was not significant in 
pneumonia patients (p=0.251). 
 These findings for LL-37 are consistent with those of Gombart et al.39 who 
showed that the cathelicidin precursor, hCAP-18, was strongly associated with 
mortality in patients undergoing haemodialysis, but did not have a statistically 
significant relationship with vitamin D. In addition, thirty patients in the present 
study used supplements to boost their vitamin D intake. Comparison of these 
patients with those not taking additional vitamin D showed that while 25D levels 
were significantly increased in the supplemented group (p=0.0001), LL-37 was 
not (p=0.835). 
 No association was found between hBD-2 and 30-day mortality in 
pneumonia (p=0.262) or COPD (0.797). This remained the case when assessing 
the two infections together (0.803), and after adjusting for low vitamin D, 
cathelicidin level, age, sex, diagnosis, CURB65 and Charlson index. 
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 Lower plasma levels of LL-37 were found to be associated with increased 
mortality in COPD patients and, despite the lack of statistical significance, 
showed a similar trend in pneumonia (Figure 3.3 b). This is consistent with the 
hypothesis that lower antimicrobial peptide levels reduce the effectiveness of the 
innate immune response, and result in infections with a higher severity. In this 
case, severity was measured in terms of 30-day mortality, as the relationship 
between LL-37 and CURB65 was not statistically significant (Figure 3.1). This 
increased mortality in patients with lower LL-37 levels lends further support to 
the idea that this antimicrobial peptide is essential to human survival, as is clearly 
demonstrated in morbus Kostmann patients. 
 It is possible that hBD-2 levels do not show such a relationship with 30-
day mortality because they are not as indispensable as LL-37. This may be due to 
the fact that humans have several β-defensin genes, but only one for cathelicidin. 
These different defensins have a certain degree of overlap in their tissue 
distribution, and therefore may be able to substitute for one another to a certain 
extent. Alternatively, one of the other defensins may hold a greater importance in 
these respiratory tract infections than hBD-2, and it may be this peptide that is 
significantly related to mortality. 
 
3.4 MALDI-TOF as a method for screening plasma LL-37 
Although not a quantitative method like ELISA, it was thought that 
MALDI-TOF mass spectrometry might be able to detect LL-37 in plasma, down 
to a certain concentration. If so, screening plasma samples to determine which 
patients had LL-37 levels below this detection threshold, could provide a fast and 
simple method for identifying those with a higher risk of mortality. 
To determine the feasibility of this method, the six plasma samples with 
the highest LL-37 levels (as determined by ELISA) were screened. Spectra 
obtained were compared to those generated by MALDI-TOF analysis of the 
human LL-37 ELISA standard (Figure 3.4). The peaks at approximately 4.56 kDa 
were in good agreement with that of the standard, and were seen in five of the six 
plasma samples. Peaks at about 9.2-9.3 kDa were also evident in the standard and 
at least two samples, and may represent aggregates of cathelicidin molecules. A 
sample spectrum is shown in Figure 3.5, for comparison.  
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Figure 3.4 – MALDI spectrum of LL-37 standard 
 
 
Figure 3.5 – MALDI spectrum of a plasma sample 
 
The hBD-2 standard was also run on the mass spectrometer, and compared 
to sample spectra to determine if the plasma screens could also detect this 
antimicrobial peptide. Although some sample peaks did resemble those of the 
standard, hBD-2 levels in plasma are much lower than those of LL-37 (pg/mL 
compared to µg/mL), making detection less likely. Therefore, even if a threshold 
could be obtained, it is likely that it would be at a high concentration, and would 
therefore not be useful for plasma screens. In any case, hBD-2 levels were not 
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found to be significantly associated with mortality in either respiratory disease, so 
the ability to identify patients with lower levels by MALDI-TOF did not have the 
same clinical potential or importance.  
 
3.5 Tris-Tricine SDS-PAGE detection of LL-37 
 For the plasma screening method to be used, the identity of the peak at 
4.56 kDa needed to be confirmed as LL-37. This required the use of gel 
electrophoresis, to allow for a more complete purification of LL-37 from other 
plasma proteins. Bands of interest were excised from the gels and subjected to a 
tryptic digest, followed by MALDI-TOF. The spectra produced by mass 
spectrometry can act as a fingerprint for each protein or peptide, and help in 
identification when compared to a database. 
Attempts to purify LL-37 by gel electrophoresis were made problematic 
due to the small size and low abundance of the peptide in patient plasma. The size 
of the mature peptide (4.5 kDa) made traditional Laemmli SDS-PAGE gels 
unsuitable, so the Tris-Tricine method was employed, as these gels achieve better 
separation of low molecular weight proteins. To further increase this separation, 
the use of highly concentrated gels (12.5 to 16%) and a higher cross linking 
percentage were suggested57.  
 Figure 3.6 shows an image of a 16% Tris-Tricine gel with 3% cross-
linking. Lanes 8-9 show the necessity for purification steps prior to 
electrophoresis, as the abundant plasma protein albumin masks other high 
molecular weight bands, and distorts those of a low molecular weight. Lanes 4-7 
show reasonably good separation and resolution, and a number of bands were 
extracted for subsequent mass spectrometric analysis. However, as indicated by 
their faintness, these bands were of low abundance peptides, and did not produce 
significant database hits. In addition, bands in the LL-37 standard lanes (2-3) 
appeared at a higher mass than would be expected (arrows 2 and 3), suggesting 
the presence of material other than the antimicrobial peptide (e.g. some form of 
preservative). 
 As LL-37 is processed from a precursor (hCAP-18), which has a 
molecular weight of 16-18 kDa, sample bands of around this size were also 
extracted for analysis by MALDI-TOF. Bands of an appropriate size were 
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identifiable in the Tris-Tricine gels (e.g. Figure 3.6, arrow 1), but did not produce 
significant hits when the spectra were compared to a database. 
 
 
Figure 3.6 – 16% Tris-Tricine gel with 3% cross-linking 
Arrows indicate bands extracted for MALDI analysis 
 
Lane 1: 10 µL ladder; Lane 2: 10 µL LL-37 standard (1:1 with GLB); Lane 3: 
10 µL LL-37 standard with 0.2 µg/µL formic acid (1:1 with GLB); Lane 4-7: 
10 µL sample (albumin removal/TCA pellet resuspended in 40 µL water, 1:1 with 
GLB, supernatant loaded); Lane 8-9: 10 µL sample plasma (1:1 GLB) 
 
 
As shown in Figure 3.7a, the methanol/acetic acid (Me/Ac) precipitation 
method for plasma purification did not produce the same clean banding pattern as 
the albumin removal and TCA precipitation method (Figure 3.7b). This may have 
been because the albumin was not specifically removed in the Me/Ac method, so 
could have impacted the resolution of other bands.
2 
 
3 
Lane     1      2      3      4       5      6       7               8  9 
1 16950 Da  
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Figure 3.7 – 16% Tris-Tricine gel with 3% cross-linking, blue-silver stained 
 
a) Lane 1: 20 µL ladder; Lane 2: 20 µL LL-37 standard (100 µL dried in 
SpeedVac plus 30 µL GLB); Lane 3: 20 µL LL-37 with 0.2 µg/µL formic acid 
(2:1 with GLB); Lane 4-5: 20 µL samples (Me/Ac precipitated, in 50µL GLB) 
 
b) Lane 1: 10 µL ladder; Lane 2: 10 µL LL-37 standard (2:1 with GLB); Lane 3: 
hBD-2 standard (2:1 with GLB), Lane 4-8: 10 µL samples (albumin removal/TCA 
pellet in 40 µL water, 1:1 with GLB, supernatant loaded) 
  
 6512 
 3496 
 1 
16950 
Da 
26625 
14437 
Lane      1               2     3             4      5 
a) 
b) 
 
3 
Da 
2 
14437 
16950 
26625 
Lane      1      2      3      4      5      6      7      8 
Results and Discussion  53 
Regardless of the purification technique used, MALDI analysis only 
produced positive identifications for the most abundant peptides present in the 
fraction submitted to gel electrophoresis. These were apolipoprotein A-I and 
serum amyloid A protein (SAA1), the most significant hits for which are 
displayed in Table 3.3. 
 
Table 3.3 – Positive identifications and significance levels from MALDI-TOF 
analysis of bands extracted from Tris-Tricine gels 
 
Hit 
Molecular 
weight 
(Da) 
Mascot score 
(>73 for 
significance) 
Figure 
showing 
band 
352 
Figure 3.7a 
(band 1) Apolipoprotein A-I 
gi/90108664 
28061.470 
155 
Figure 3.7b 
(band 2) 
Serum amyloid A1 
gi/13937839 
13524.500 110 
Figure 3.7b 
(band 3) 
See Appendix 6.4 for full MALDI results 
 
An interesting observation is that the ladder appears to run slightly higher 
than the samples. For example, in Figure 3.7b, the apolipoprotein band of 
approximately 28 kDa was positively identified below the highest molecular 
weight band of the ladder (triosephosphate isomerase, ~26 kDa). This suggests 
that potential LL-37 bands may actually be further down the gel than expected. In 
addition, not all bands of the ladder were always seen with blue-silver staining. 
Figure 3.8 shows a comparison of blue-silver (a) and silver (b) staining on 
the same 16% Tris-Tricine gel. Silver staining allowed visibility of more sample 
bands, and the two lowest molecular weight ladder bands, which could not be 
seen with blue-silver. However, even with this increased stain sensitivity, only 
faint bands were seen in the LL-37 standard lane, and only one of these (indicated 
by an arrow) appeared near the expected molecular weight. 
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Figure 3.8 – 16% Tris-Tricine gel with 6% cross-linking, stained with  
blue-silver (a) and silver (b)  
(Arrow indicates potential LL-37 band in standard lane) 
 
3.6 Lysozyme gels 
 A range of concentrations of lysozyme were run on small 16% Tris-
Tricine gels, to determine the concentration threshold for detection by blue-silver 
staining. The lowest protein load visible was 1 ng, with a possible faint band at 
0.5 ng (Figure 3.9). Even fainter band-like patterns can also be seen in the control 
lane (0 ng) and in the 0.1 ng lane, suggesting heavy well loading may have caused 
splash-over into other wells and produced bands where lysozyme would otherwise 
not have been detected. This conclusion is supported by the fact that the group 
responsible for developing this staining protocol reported a detection limit of 1 ng, 
with the possibility of 0.75 ng as the minimal detectable load for BSA62. In 
addition, this low detection was not reproducible in the current study, as several 
repeats of the experiment failed to produce bands at loads of below 100 ng.  
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Figure 3.9 – 16% Tris-Tricine gel with 3% cross-linking, showing detection 
limit for blue-silver staining 
 
 MALDI-TOF mass spectrometry has been reported to be capable of 
detection at the subpicomole level. This high sensitivity relies on sample purity, 
and the electrophoretic separation of the diversity of proteins in plasma is 
therefore a very important preparative step. However, separation is only useful if 
the protein or peptide of interest can be detected and extracted from the gel. This 
means that, if the stain used cannot visualise the desired protein, the sensitivity of 
the MALDI becomes irrelevant63. 
One method that enables a lower detection limit to be reached is silver 
staining, which can visualise protein loads of down to 1-10 ng.  However, it is 
widely accepted that this technique is unsuitable in cases where subsequent 
MALDI-TOF mass spectrometry of the stained proteins is required. This 
incompatibility results from the use of Ag+ and sensitizing agents (particularly 
glutaraldehyde), which can cause protein destruction or modification, and thereby 
impede protein identification64.  
Two other techniques were performed on gels with the same lysozyme 
concentration gradient, to determine whether the detection threshold could be 
lowered, while improving MALDI compatibility through slight modifications of 
the silver staining protocol. However, these methods did not improve detection 
over that of the blue-silver stain, and had poorer band resolution (results not 
shown). 
Another suggestion for improving the MALDI results was to increase the 
amount of material subjected to analysis. Taking single plugs from each band for 
tryptic digestion and mass spectrometry was compared to whole band extraction, 
to see if more material allowed for better detection, or whether the background 
Load (ng):     0   1000   500   100    50     10      5      1      0.5    0.1 
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was also increased. Single plug/whole band comparison was carried out for dried 
droplet and thin layer target loading techniques, to determine which method 
produced better peak resolution. Inclusion of a wash step improved the spectra for 
both dried droplet and thin layer techniques, and the thin layer/wash method 
produced the highest peak intensity overall, particularly when the whole band was 
used (Figure 3.10).  
 
  
Figure 3.10 – Comparison of MALDI preparation techniques for single plug 
and whole band extraction from Tris-Tricine gels 
DD – dried droplet; TL – thin layer; NW – no wash; W – wash 
 
3.7 Discussion of Tris-Tricine SDS-PAGE and MALDI-TOF of 
LL-37 
Despite using the Tris-Tricine method, high gel concentrations, increased 
cross-linker percentage, more sensitive staining procedures and different mass 
spectrometry target-laying techniques, LL-37 could not be isolated by gel 
electrophoresis and identified by MALDI-TOF. This prevented further 
development of the plasma screening method because, although the sample 
spectra contained peaks that resembled those seen in the standard, it could not be 
confirmed that they were the peaks of interest.  
The low abundance of LL-37 caused problems in this study; particularly as 
the maximum concentration measured in the patient cohort only reached 
341.25 ng/mL. This is substantially lower than the 1.2-1.8 µg/mL that has been 
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reported in plasma, and it is uncertain why the patient levels were so reduced. One 
possibility is that the concentration was reported in the context of the precursor 
protein (hCAP-18), while the mature peptide (LL-37) was measured in the present 
study. Alternatively, as LL-37 is the active antimicrobial peptide and is involved 
in the innate immune response, it may have become depleted in the study patients 
as a result of consumption during infection. 
Further development of this method may require western blots to be 
employed, to allow more sensitive detection than the 100 ng limit observed for 
blue-silver and modified silver staining. The specificity of antibodies used in 
western blots may help combat the low plasma levels of this peptide being a 
barrier to detection.  
Only two proteins could be positively identified by MALDI – SAA1 and 
apolipoprotein A-I, both of which are of much higher abundance than LL-3765. Of 
particular interest to this study is apolipoprotein A-I, which is thought to sequester 
LL-37 in the bloodstream. The presence of this protein in these gels lends support 
to the assumption that LL-37 was not removed during the purification procedures. 
Effective isolation of LL-37 from other plasma proteins (particularly those 
of greater abundance) is likely to lead to successful identification of the peptide 
by mass spectrometry. This is because proper separation would produce a much 
purer extract for use in MALDI, which would allow the high sensitivity of the 
instrument to be utilised.  
Once the identity of the LL-37 peaks has been confirmed, the next step in 
developing the plasma screening method would be to trial different target loading 
techniques. If the sample distribution on the target is not homogenous, proteins 
(including LL-37) may clump together to form “hot spots”, while other regions 
will largely be composed of matrix. In these cases, directing the laser at different 
parts of the target spot yields significantly different spectra, as all the sample 
becomes localised. This would complicate determination of the threshold for 
detection of LL-37. An homogenous distribution however, would allow 
representative spectra to be collected from any point on the target. This would 
allow the threshold be identified more easily, and it could be determined with 
confidence whether a sample fell above or below this level, which is the basis for 
the clinical utility of this method. 
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3.8 DBP polymorphism determination by PCR, a pilot study 
During the course of this research project, a paper was published by Fu et 
al.47 that reported differences in serum 25-hydroxyvitamin D3 (25D) levels in 
individuals with polymorphic variants of the vitamin D binding protein (DBP) 
gene. These polymorphisms were also shown to influence the effectiveness of 
vitamin D supplementation. As the variants have been identified in a wide range 
of ethnic groups, influence vitamin D levels, and are possible candidates for the 
genetic factor predisposing certain individuals to COPD, these findings had 
important implications for this study. 
Unfortunately, the application approved by the Northern Y ethics 
committee did not cover the use of patient DNA. Extension of this approval to 
include DNA work would have required further patient consent, and was therefore 
not obtainable within the time constraints of this project. Instead, twenty 
volunteers from the University of Waikato research laboratories supplied DNA 
(via a saline mouthwash), which was genotyped to identify DBP polymorphisms. 
The purpose of this pilot study was to determine whether the same variants were 
present in a New Zealand population, and to develop a method that could later be 
used to identify DBP genotypes in the study patients. 
 The method of Fu et al. used a mutant reverse primer that was designed in 
such a way as to make mutant (K allele) bands 21 bp longer (270 bp) than wild-
type bands (249 bp). In practice however, it was extremely difficult to distinguish 
the two alleles, so the majority of heterozygotes were overlooked and could only 
be identified through subsequent sequencing. Figure 3.11 shows a 2% PCR gel 
with heterozygotes in lanes 1, 3 and 4, where a faint mutant band can be seen. 
However, this was the only gel in which these could be identified, and sequencing 
every sample would have been costly and impractical. 
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Figure 3.11 – 2% Agarose/1x TAE gel of PCR-amplified DBP products, 
multiplex system 
(From left: TK, TT, TK, TK, TT, TT, x, negative, 100 bp ladder) 
 
 It was suggested that running the PCR reaction as a multiplex was causing 
the mutant bands to appear faint, perhaps as a result of more efficient 
amplification by wild-type primers. This could not be confirmed however, as 
carrying out a separate PCR reaction for each sample (i.e. one using the wild-type 
reverse primer and the other using the mutant) also produced gels with faint 
mutant bands (Figure 3.12).  
 
 
Figure 3.12 – 2% Agarose/1x TAE gel of PCR-amplified DBP products, 
duplex system 
(From left: TT mutant, TT wild-type, TK mutant, TK wild-type, x, mutant 
negative, wild-type negative, 100 bp ladder) 
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 To improve the method, alternative PCR conditions were used in an 
attempt to increase the brightness of the mutant bands, to at least match that of the 
wild-type. The touchdown protocol effectively produced the desired resolution, 
and Figure 3.13 shows a gel with an example of each genotype (i.e. TT, TK and 
KK). 
 
 
Figure 3.13 – 2% Agarose/1x TAE gel of touchdown PCR products 
(From left: TK mutant, TK wild-type, x, TT mutant, TT wild-type, x, KK mutant, 
KK wild-type, x, mutant negative, wild-type negative, 100 bp ladder) 
 
 The T436K results of this study and those of Fu et al. are shown in 
Table 3.4, and both identified the homozygous KK genotype as the most rare. 
However, TK had the highest frequency in this study, while Fu et al. found TT to 
be the most common. 
  
Table 3.4 – Comparison of T436K and D432E allele frequencies from this 
study and that of Fu et al. 
 
SNP Alleles 
Pilot study allele 
frequency (n=20) 
Fu et al. allele 
frequency (n=98) 
TT 7 (35%) 50 (51%) 
TK 12 (60%) 33 (34%) T436K 
KK 1 (5%) 6 (6%) 
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Samples were also subjected to HaeIII digestion, to determine the D432E 
genotype. The recognition site for this enzyme was only present in the E allele 
sequence, meaning that D bands remained uncut. As the PCR gels of all but one 
individual showed a T allele band, the PCR-amplified mixtures from the wild-type 
reactions were used for the restriction enzyme digestion. Therefore, homozygous 
DD individuals retained the 249 bp band, which was cut into two bands (221 and 
28 bp) in EE homozygotes, and all 3 bands were present in heterozygous (DE) 
individuals (Figure 3.14).  
 
Note: in the KK individual, the mutant band was used instead, with expected band 
sizes of 270 bp (DD), 221 and 49 bp (EE), and 270, 221 and 49 bp (DE). 
 
 
Figure 3.14 – 2% Agarose/1x TAE gel of HaeIII-digested PCR products 
From left: DE, EE, EE, DE, DD, EE, EE, DD, DD, x, 100 bp ladder 
 
Four samples (two from the multiplex method and two from touchdown) 
were sequenced to ensure the whole and restriction enzyme-digested bands were 
representative of the correct genotypes. This sequencing confirmed the gel results 
for T436K (for sequences and electropherograms, see Appendix 6.5). However, 
examination of the touchdown wild-type and mutant sequences of a TK individual 
revealed that this technique is only sufficient for the D432E genotyping of TT 
homozygotes. This is because, if only the T band is analysed in TK individuals, 
D432E variation in the mutant band is ignored, and heterozygotes become 
overlooked. This would also be expected when examining these genotypes in the 
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multiplex system, as the restriction enzyme digestion of the faint mutant band is 
unlikely to be visible on the gel, in the presence of the much brighter wild-type 
bands.  
Based on this realisation, the true D432E genotype of all but one of the TK 
individuals (11 of 20 samples) could not be determined without further analysis, 
either by HaeIII digestion of the K band, or by sequencing. Fu et al.47 indicated 
that the D432E genotype was not significantly associated with serum vitamin D 
levels, and is therefore not as relevant to this study as the T436K genotype. 
However, for completeness, allele frequencies of the 9 samples with valid D432E 
genotyping (i.e. TT, KK and sequenced TK individuals) are displayed in Table 3.5 
and, despite their low sample numbers, these frequencies are reasonably 
consistent with those of the Fu et al. study. 
 
Table 3.5 – Comparison of D432E allele frequencies from this study and that 
of Fu et al. 
 
SNP Alleles 
Pilot study allele 
frequency (n=9) 
Fu et al. allele 
frequency (n=98) 
DD 2 (22%) 22 (22%) 
DE 5 (56%) 41 (42%) D432E 
EE 2 (22%) 26 (27%) 
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3.9 Proteomic approach for identification of DBP genotype 
As an alternative to DNA work, a proteomic approach was employed in an 
attempt to distinguish Gc1 and Gc2 genotypes in a way that remained within the 
approved ethical guidelines. This approach was based on the work of Kitchin and 
Bearn66, who demonstrated the ability to identify Gc1-1, 1-2 and 2-2 genotypes 
through the use of polyacrylamide gels, as each produces a different banding 
pattern, as shown in Figure 3.15.  
 
 
Figure 3.15 – Banding patterns expected for different Gc-globulin genotypes, 
as published by Kitchin and Bearn66 
 
The molecular weight of the DBP protein (~51 kDa) made the use of 
Laemmli gels more suitable than the Tris-Tricine method. Figure 3.16 shows a 
photo of a 7% Laemmli gel loaded with 2.5 µL plasma (diluted 1:50 in GLB) per 
well, and 20 µL ladder (Bio-Rad Precision Plus Protein Standards (Dual Colour), 
161-0374). 
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Figure 3.16 – 7% Laemmli gel of diluted plasma samples, arrows indicate 
bands extracted for MALDI analysis 
 
Albumin has a molecular weight of approximately 66 kDa, and is the most 
abundant protein in human serum, constituting about 50% of the total protein 
content. This is increased to over 95%, when the other eleven high abundance 
proteins are also included65. Therefore, the huge diversity of proteins found in 
serum falls largely within the remaining 5%, indicating that they are of relatively 
low abundance. A paper by Hortin et al.65 ranked 150 proteins according to the 
amounts present in healthy human plasma. Among the top ten were albumin, 
various immunoglobulins, apolipoprotein A-I (see section 3.7), and fibrinogen. 
Gc-globulin was ranked 25th, with a concentration of 8-14 µmol/L. Although 
listed quite highly in terms of abundance, these levels are relatively low when 
compared to the 500-800 µmol/L of albumin. 
Table 3.6 shows the Mascot hits for the bands indicated in Figure 3.16. 
Three significant hits were obtained for band 1, and all indicate that it is likely to 
be albumin, as expected based on the molecular weight and intensity. Although it 
does not have the highest score, the molecular weight of hit 3 is closest to that 
expected. Bands 2 and 3 were identified as being related to fibrinogen. As the β-
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chain of fibrinogen was ranked 18th by Hortin et al. with a concentration of 10-
27 µmol/L, all the proteins identified were of higher abundance than Gc-globulin. 
Based on the molecular weights of these bands, Gc-globulin should be in the same 
area, between albumin and fibrinogen β-chain (i.e. bands 1 and 2). 
 
Table 3.6 – Positive identifications and significance levels from MALDI-TOF 
analysis of bands extracted from Laemmli gels 
 
Hit 
Molecular 
weight 
(Da) 
Mascot score 
(>73 for 
significance) 
Figure 
showing 
band 
Hit 1: Albumin-like 
gi/763431 
52048 91 
Hit 2: Albumin, isoform 
CRA_t [Homo sapiens] 
gi|119626083 
58614 86 
Hit 3: Chain A, Structure Of 
Human Serum Albumin 
With S-Naproxen And The 
Ga Module 
gi|168988718 
65778 86 
Figure 3.16 
(band 1) 
Fibrinogen beta chain, 
isoform CRA_f [Homo 
sapiens] 
gi|119625340 
44153 82 
Figure 3.16 
(band 2) 
Chain C, Crystal structure of 
recombinant human 
fibrinogen fragment D 
gi|24987625 
35155 82 
Figure 3.16 
(band 3) 
   See Appendix 6.4 for full MALDI results 
 
As the Gc-globulin bands run so close to albumin, gradient gels of 7-10% 
were used as a means of increasing separation. However, this closeness made it 
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extremely difficult to run the gel in such a way as to distribute the Gc bands in the 
lower percentage section, while retaining albumin in the 10% separating gel. 
Despite this, one such gradient gel did produce some Gc-like banding, which can 
be seen in the magnified section of Figure 3.17. Arrow 1 indicates a cluster of 
three bands (although difficult to distinguish from each other in the photo), which 
could represent an individual with the Gc1-2 genotype. The two bands indicated 
by arrow 2 appear in line with the upper and middle of the three bands, indicative 
of Gc1-1. However, this could not be confirmed by subsequent MALDI analysis. 
 
 
 
Figure 3.17 – Gradient gel of diluted plasma samples showing increased 
magnification of relevant section 
 
Although a significant improvement over the single concentration 
separating gel (Figure 3.16), this resolution would need to be further improved 
before the polymorphic variants could be confidently identified. This may include 
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the incorporation of a purification step before gel electrophoresis, such as that 
used by Christiansen et al.44, which allowed the successful isolation of Gc-
globulin from plasma. However, this group used a large-scale method, which was 
not practical for this study, as comparison of small volumes of patient plasma was 
required. Alternatively, band resolution could be increased if a step for the 
removal of albumin was included. As DBP is a member of the same superfamily 
as albumin, this step would have to be highly specific, to prevent the removal of 
both proteins. 
More recent proteomic methods for identifying Gc-globulin variants tend 
to involve immunoelectrophoresis or isoelectric focussing. However, these 
methods require the purchase of specific antibodies that are able to distinguish 
between each Gc isoform, to allow visualisation of the different variants. The 
most effective method in terms of results, simplicity, and sample throughput was 
PCR; so future work on this study should aim to gain ethical approval for 
analysing DBP polymorphisms using patient DNA. 
The only real difficultly with using the stored plasma samples for PCR is 
the extraction of DNA. However, the recently published method of Xue et al.67 
was found to be effective in the isolation of cell-free DNA, such as that contained 
in plasma. 
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4. Conclusions 
 
The health benefits of vitamin D have been studied for a long time. Until 
recently however, these studies have largely focussed on its role in maintaining 
bone health and skeletal integrity, particularly in relation to the prevention of 
rickets in children. This involvement in bone metabolism is now well known, and 
is commonly referred to as the main function of the vitamin. More recent findings, 
such as those indicating the widespread distribution of vitamin D receptors in the 
body, and the correlation between latitude and incidence rates for a number of 
diseases, have inspired renewed interest in this hormone, and led to the discovery 
of its involvement in a multitude of other biological processes. 
The aim of this research was to explore the relationship between the 
plasma levels of vitamin D and the antimicrobial peptides LL-37 and hBD-2 in 
patients with pneumonia or exacerbations of COPD. Many studies have indicated 
that vitamin D plays a role in the regulation of such peptides via response 
elements in the gene promoters, so it was hypothesized that 25D levels would 
correlate with peptide concentration. As these peptides constitute an essential part 
of the innate immune response, it was also hypothesized that individuals with 
reduced peptide production would suffer from more severe infection (i.e. higher 
CURB65 scores) and have a greater risk of mortality. Although these hypotheses 
where not supported by the results, this research did produce several important 
findings.  
Firstly, the finding that severe vitamin D deficiency (i.e. <30nmol/L) was 
significantly associated with increased mortality in both infections, has important 
implications for clinical treatment, as it suggests that vitamin D supplementation 
has the potential to reduce the risk of death. Further research would be required to 
identify the precise 25D threshold below which survival becomes reduced, and 
clinical trials could help determine whether boosting these levels would bring 
about the expected drop in mortality. 
Secondly, to the best of my knowledge, this is the first study to identify a 
relationship between LL-37 and mortality in COPD, and studies designed to 
ascertain whether boosting these levels could aid in treatment would also be 
valuable. 
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Further development of the MALDI-TOF screening method could be 
useful in the meantime, to help rapidly identify patients most at risk of death. 
Based on this research, the main barrier to the success of this method was the 
detection of LL-37 after electrophoretic separation. None of the methods 
employed here allowed visualisation of this small, low abundance peptide, which 
prevented effective isolation for mass spectrometry. Future work should focus on 
using antibodies for detection, as the levels in the patient plasma are particularly 
low.  
Both vitamin D and LL-37 seem to be significant determinants of 
mortality in these diseases, where low levels increase the risk in both cases. Based 
on the lack of association between the two variables however, their effects on 
survival appear to be independent. Further research into the interplay between 
vitamin D and LL-37 in the context of these infections would be interesting, as the 
presence of VDREs in the cathelicidin gene promoter, and the ability of vitamin D 
to upregulate expression of the AMP in vitro suggest some form of connection 
must exist. It seems possible that LL-37 could be associated with active 1,25D, 
and that its relationship with 25D is therefore indirect. 
Another aspect worthy of further attention is the vitamin D binding protein 
(DBP). It would be interesting to use the PCR method developed in this project to 
assess the DBP polymorphisms of the study patients for two main reasons. Firstly, 
the DBP genotype Gc1F is thought to predispose its carriers to COPD, while the 
Gc2-2 genotype is believed to be protective. Analysis of the frequency of each 
isoform in the COPD group would allow determination of whether such a 
relationship exists in this cohort, or whether these associations are population-
specific.  
More relevant to the study group as a whole, would be to compare the 
T436K genotype with 25D levels to determine whether baseline vitamin D is 
influenced, as suggested by Fu et al.47 This SNP is also thought to influence how 
an individual will respond to vitamin D supplementation which, coupled with the 
finding that low vitamin D increases rates of mortality, has a broader relevance to 
this study. Integrated clinical studies incorporating both of these findings would 
have to be employed to prevent the production of erroneous results. That is, when 
determining if vitamin D supplements can reduce mortality in these respiratory 
Conclusions  70 
infections, they would have to be administered based on DBP genotype, to 
account for differences in subject responses. 
In this modern world of increasing antibiotic resistance and the everlasting 
search for new therapeutic drugs, it is somewhat ironic that it be compounds such 
as vitamin D and antimicrobial peptides – products synthesised by the body and 
studied for many years, that would prove to be of such integral importance to 
human survival, and the subject of renewed interest on a seemingly exponential 
scale. This study provides yet another context in which they show significance, 
and presents findings that suggest potential clinical importance for these natural 
antibiotics and the “sunshine vitamin”.
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6. Appendices 
 
6.1 Buffers and solutions 
6.1.1 Human β-defensin 2 (hBD-2) ELISA 
 
Phosphate Buffered Saline (PBS) 
8 g NaCl 
0.25 g KCl 
0.2 g KH2PO4 
1.15 g Na2HPO4 
Make up to 1L with dI water. Check pH is approx. 7.20 (7.0 – 7.4 is acceptable), 
and autoclave 
 
Wash Buffer 
0.05% Tween-20 in PBS 
Make 1 L PBS and add 0.5 mL Tween-20. Check pH as above, and autoclave 
 
Block Buffer 
1% BSA in PBS 
Store at 4 °C 
 
Diluent 
0.05% Tween-20, 0.1% BSA in PBS 
Store at 4 °C 
 
6.1.2 Tris-Tricine SDS-PAGE solutions 
 
AB-3 (49.5% T, 3% C) 
48 g acrylamide 
1.5 g N, N’-methylenebisacrylamide 
100 mL Milli-Q 
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AB-6 (49.5% T, 6% C) 
46.5 g acrylamide 
3 g N, N’-methylenebisacrylamide 
100 mL Milli-Q 
 
1x Anode Buffer (0.2 M Tris-Cl, pH 8.9) 
24.22 g Tris base 
500 mL water 
Adjust to pH 8.9 with concentrated HCl 
Dilute to 1 L with water 
 
1x Cathode Buffer (0.1 M Tris, 0.1 M Tricine, 0.1 % (w/v) SDS) 
12.11 g Tris base 
17.92 g Tricine 
1 g SDS 
Dilute to 1 L with water 
 
Tris-Cl/SDS, pH 8.45 (3.0 M Tris-Cl, 0.3 % SDS)   (AKA Gel Buffer) 
182 g Tris base 
300 mL water 
Adjust pH to 8.45 with 1 N HCl 
Dilute to 500 mL with water, and add 1.5 g SDS 
 
Tricine Sample Buffer (0.1 M Tris, 24 % (w/v) glycerol, 8% (w/v) SDS, 0.2 M 
DTT, 0.02 % (w/v) Coomassie Blue G-250)  (AKA Gel Loading Buffer) 
2 mL 4x Tris-Cl/SDS, pH 6.8 
 2.4 mL (3.0 g) glycerol 
0.8 g SDS 
0.3 g DTT 
2 mg Coomassie Blue G-250 
Add water to 10 mL and mix before making aliquots and storing at -20 °C 
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6.1.3 Laemmli gel solutions 
 
30% acrylamide/0.8 % bisacrylamide 
30 g acrylamide 
0.8 g N, N’-methylenebisacrylamide 
Add water to 100 mL total volume 
Filter and store at 4 °C in the dark 
 
4x Tris-Cl/SDS, pH 6.8 (0.5 M Tris-Cl, 0.4 % SDS) 
Dissolve 6.05 g Tris base in 40 mL water. Adjust to pH 6.8 with 1N HCl. Add 
water to final volume of 100 mL. Filter and add 0.5 g SDS. 
 
4x Tris-Cl/SDS, pH 8.8 (1.5 M Tris-Cl, 0.4% SDS) 
Dissolve 91 g Tris base in 300 mL water. Adjust to pH 8.8 with 1N HCl. Add 
water to final volume of 500 mL. Filter and add 2 g SDS. 
 
5x SDS electrophoresis buffer 
7.55 g Tris base 
36.0 g glycine 
2.5 g SDS 
Add water to 500 mL total volume, and dilute to a 1x working solution when 
appropriate. 
 
2x SDS sample buffer 
2.5 mL 4x Tris-Cl/SDS, pH 6.8 
2.0 mL glycerol 
0.4 g SDS 
0.31 g DTT 
Add water to 10 mL and mix, then store in aliquots at -20 °C. 
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6.1.4 Blue-silver staining solutions 
 
Fixer (50 % methanol, 2% phosphoric acid) 
250 mL methanol 
10 mL phosphoric acid 
Make up to 500 mL with water 
 
Blue Micellar Solution 
1.2 g Coomassie Blue G-250 
100 g ammonium sulphate 
200 mL methanol 
100 mL phosphoric acid 
700 mL water 
 
Completely dissolve Coomassie in methanol before adding other ingredients, to 
prevent stain forming lumps in solution. 
 
Destain (5% methanol) 
25 mL methanol 
475 mL water 
 
6.1.5 Silver staining solutions 
All silver staining solutions were made up in Milli-Q water 
 
a) Basic silver saining 
Fixer 
50% ethanol 
12% acetic acid 
 
Sensitizer 
0.02% sodium thiosulfate (2 mL 1% stock in 98 mL Milli-Q) 
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Stain 
10 mL 1% silver nitrate stock 
90 mL Milli-Q 
100 µL 37% formaldehyde 
 
Developer 
100 mL 3% sodium carbonate 
100 µL 37% formaldehyde 
1 mL 1% sodium thiosulfate 
 
b) He Silver Staining 
Fixer 
30% ethanol 
10% acetic acid 
 
Sensitizer 
30% ethanol 
4.1% sodium acetate 
0.2% sodium thiosulfate 
 
Stain 
0.1% silver nitrate 
0.02% formaldehyde 
 
Developer 
2.5% sodium carbonate 
0.01% formaldehyde 
 
c) Yan Silver Staining 
Fixer 
40% methanol 
10% acetic acid 
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Sensitizer 
30% methanol 
0.2% sodium thiosulfate 
6.8% sodium acetate 
 
Stain 
0.25% silver nitrate 
 
Developer 
2.5% sodium carbonate 
0.04% formaldehyde 
 
6.1.6 MALDI-TOF mass spectrometry 
Calibration standard, CHCA and sDHB matrices, and targets were all purchased 
from Bruker Daltonics. 
 
The peptide calibration standard contained the following peptides: 
Angiotensin II, Angiotensin I, Substance P, Bombesin, ACTH clip 1-17, 
ACTH clip 18-39, Somatostatin 28 
 
6.1.7 DNA extraction from saline mouthwash 
Lysis Solution 
35 mL water 
5 mL 1M Tris, pH 9.0 
5 mL 0.5M EDTA 
5 mL 10% SDS 
1 mL 5M NaCl 
 
6.1.8 PCR solutions 
10x PCR Buffer 
- 300mM Tris-HCl (pH 9.0) 
- 300mM salts containing of K+ and NH4+ 
- 20mM Mg2+ 
- Enhancer solution 
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Master Mix 
1 mL 10x PCR buffer (w/ 20mM MgCl2) 
1 mL dNTPs (2.5mM each) 
8 mL water 
 
iStarTaq polymerase (iNtRON) was used at 1.25U per 50 µL reaction 
 
6x Loading Buffer 
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol FF 
15% Ficoll (type 400) 
Made up to desired volume with distilled water 
 
50x Tris-acetate EDTA (TAE) buffer 
242 g Tris base dissolved in 800 mL water 
57.1 mL glacial acetic acid 
100 mL 0.5 M EDTA (pH 8.0) 
Make up to 1L with water 
 
1x TAE running buffer 
Dilute 20 mL 50x TAE stock with 980 mL water 
 
2% Agarose/1xTAE gel with ethidium bromide 
For one gel (approximately 30 mL): 
0.6 g agarose 
30 mL 1x TAE 
Microwave until agarose is dissolved, then cool in a water bath before adding 
3 µL 10 mg/mL ethidium bromide stock (1 µL per 10 mL agarose/TAE). Pour 
into gel apparatus and leave to set. 
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6.2 PCR primer sequences 
 
Common Forward:  
5’-GGCATGTTTCACTTTCTGATCTC-3’ 
 
Wild-type Reverse:  
5’-ACCAGCTTTGCCAGTACCG-3’ 
 
Mutant Reverse:  
5’-GCAAAGTCTGAGTGCTTGTTATGCAGCTTTGCCAGTTGCT-3’ 
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6.3 Vitamin D and ELISA results 
6.3.1 Example calculation of peptide concentration 
 
 LL-37 and hBD-2 levels were determined from ELISA standard curves. 
The average absorbance of each duplicate set was used in the standard curve 
equation to give the peptide concentration. If the difference between the duplicate 
absorbance readings was greater than 15%, the ELISA for that sample was 
repeated. An example standard curve and dataset is shown below for hBD-2 
ELISA. 
 
Standard 
concentration 
(pg/mL) 
Wavelength-
corrected mean 
absorbance 
Blank 
absorbance 
Blank-
corrected 
absorbance 
1 0.2500 0.1154 0.1346 
10 0.2603 0.1154 0.1449 
100 0.7233 0.1154 0.6080 
1000 1.3256 0.1154 1.2103 
 
Standard curve generated by plotting standard concentration against blank- and 
wavelength-corrected mean absorbance: 
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Example of ELISA data processing and calculation of plasma concentration 
Raw data: 
 Absorbance at 405 nm 
(after 30 min) 
Absorbance at 690 nm 
Blank 0.4809 0.3731 
Blank 
(duplicate) 
0.4929 0.3700 
Mean 0.4869 0.3716 
Percentage 
Difference 
2.4646 0.8343 
 
 Absorbance at 405 nm 
(after 30 min) 
Absorbance at 690 nm 
Sample 1 1.5257 0.8176 
Sample 1 
(duplicate) 
1.5271 0.8204 
Mean 1.5264 0.8190 
Percentage 
Difference 
0.0917 0.1834 
 
Wavelength correction: 
Corrected wavelength = Absorbance at 405 nm - Absorbance at 690 nm 
i.e. Blank  = 0.4869 - 0.3716 
   = 0.1153 
 Sample 1 = 1.5264 - 0.8190 
   = 0.7074 
 
Blank correction (to account for background effects): 
Corrected wavelength = Sample absorbance - Blank absorbance 
i.e.   = 0.7074 - 0.1153 
   = 0.5921 
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Determination of concentration: 
The mean corrected absorbance is substituted in the place of x in the standard 
curve equation. 
In this example: 
y = 923.03x3 - 591.82x2 + 198.07x - 9.083 where x = 0.5921 
 
Therefore, y = 92.29 pg/mL (bold and underlined in table below) 
 
6.3.2 Raw vitamin D and ELISA results – CAP 
Vitamin D level (ng/mL) hBD-2 concentration (pg/mL) LL-37 concentration (ng/mL) 
74 840.99 83.42 
48 590.31 82.58 
22 - 263.49 
69 205.61 156.88 
37 103.35 87.3 
79 426.1 35.2 
66 608.28 189.59 
60 779.87 100.29 
110 - - 
62 92.29 21.85 
34 79.42 88.83 
71 54.62 159.03 
55 207.64 72.89 
25 187.07 165.59 
64 256.77 45.73 
42 378.13 79.67 
48 - - 
12 494.5 36.38 
90 233.95 30.35 
97 283.21 63.28 
39 1089.78 36.07 
68 - 61.31 
120 132.14 83.24 
21 210.12 60.11 
10 1467.25 147.87 
38 40.93 60.31 
48 1106.71 36.6 
61 54.72 48.9 
29 261.92 21.98 
110 647.24 42.97 
40 - 34.37 
12 1228.25 101.87 
74 201.19 38.81 
77 1145.47 68.15 
64 126.83 91.73 
32 367.39 55.29 
80 1002.35 72.28 
45 47.79 112.26 
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58 - - 
38 978.91 64.85 
25 260.36 210.64 
46 680.84 166.98 
51 1027.98 108.61 
68 412.15 123.49 
68 174.7 94.94 
71 132.21 120.69 
37 177.99 69.03 
41 162.38 65.52 
100 186.92 85.94 
94 589.46 72.76 
57 457.1 68.46 
44 504.25 37.69 
51 612.45 32.88 
96 158.35 74.98 
72 107.46 125.66 
110 29.02 60.99 
29 83.85 40.87 
120 - - 
40 59.08 75.56 
86 806.93 33.69 
54 532.14 33.94 
58 52.16 106.48 
61 724.17 62.65 
30 557.5 17.36 
20 930.6 70.81 
45 509.3 59.39 
12 428.07 166 
97 261.17 152.14 
53 199.47 61.19 
17 665.74 53.04 
20 1061.75 47.76 
33 148.45 73.26 
73 219.35 120.2 
59 215.19 85.37 
67 - 201.45 
45 - - 
56 522.58 112.13 
35 1484.17 93.54 
13 325.1 170.93 
64 195.51 39.7 
56 583.18 116.51 
64 1642.04 - 
81 302.14 49.48 
100 449.82 13.16 
82 - - 
40 77.78 65.69 
39 31.02 63.96 
66 518.95 46.72 
47 174.75 87.83 
51 106.4 191.44 
49 178.63 44.06 
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60 258.64 152.55 
26 115.17 20.72 
57 285.35 84.68 
73 13.96 22.18 
58 47.87 25.98 
56 - - 
33 242.17 69.42 
61 437.81 61.1 
53 1733.62 64.85 
53 491.76 75.19 
36 147.73 37.61 
49 119.79 43.4 
37 32.63 39.98 
54 905.83 78.98 
63 129.24 43.49 
33 83.61 51.31 
70 260.37 61.07 
140 433.7 140.7 
23 - - 
10 271.1 99.05 
36 475.27 32.79 
 
6.3.3 Raw vitamin D and ELISA results – COPD 
Vitamin D level (ng/mL) hBD-2 concentration (pg/mL) LL-37 concentration (ng/mL) 
26 154.25 73.17 
54 298.24 98.6 
64 136.82 59.99 
37 166.91 49.75 
13 332.11 52.93 
56 112.14 67.09 
50 148.8 44.99 
48 86.34 54.79 
89 96.04 49.38 
70 1125.14 74.8 
51 97.57 41.95 
85 618.25 122.61 
42 447.56 19.93 
31 71.12 111.63 
30 - - 
60 160.48 59.8 
12 106.58 94.22 
33 79.78 78.85 
49 234.8 51.25 
49 520.4 69.34 
14 235.94 61 
43 40.65 64.36 
13 586.66 59.97 
49 2469.39 35.97 
24 77.18 10.26 
42 63.9 131.66 
73 - 97.65 
41 146.98 60.13 
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35 236.52 55.51 
40 17.69 93.78 
10 - 88.31 
58 333.6 101.36 
65 77.49 31.63 
32 1416.09 72.06 
68 189.12 69.82 
52 286.61 55.43 
79 333.18 43.07 
14 2006.72 66.64 
42 420.83 55.58 
32 24.23 62.31 
49 15.31 40.91 
10 303.23 30.13 
51 188.38 341.25 
81 74.37 68.38 
66 232.31 40.13 
52 - - 
39 256.01 77.62 
35 213.96 18.37 
57 117.08 68.59 
43 68.55 29.69 
19 88.42 75.99 
49 150.39 35.85 
62 564.17 29.2 
26 1386.29 77.31 
64 346.92 83.6 
10 49.31 34.85 
53 - - 
39 249.47 18.93 
34 328.75 41.74 
50 330.92 116.55 
63 152.56 15.17 
45 148.5 51.19 
33 343.39 41.03 
61 32.74 44.02 
26 - - 
27 1366.35 66.07 
63 50 96.9 
30 194.56 65.47 
62 718.41 108.34 
54 80.2 93.64 
65 541.17 23.51 
12 81.3 50.62 
71 39.7 48.06 
Appendices  91 
6.4 Full results and spectra for MALDI hits 
6.4.1 Expanded results for Table 3.3 
i. Band 1 
• Spectrum 
 
 
• Peak list (matches shown in bold) 
m/z SN Quality Fac. Res. Intens. Area 
831.412 91.5 1145 6699 2239.02 496 
853.411 9.9 612 6635 243.94 57 
869.503 121.5 1227 7146 3040.36 678 
873.427 49.4 644 7639 1225.58 253 
887.442 57.5 733 7098 1467.42 308 
896.461 12.4 550 8340 313.36 62 
1012.557 388.1 6437 6808 9385.56 2730 
1026.563 17.7 854 8497 461.85 115 
1031.497 37.8 700 8526 957.09 244 
1045.511 81.6 1036 6974 1901.06 539 
1152.606 25.6 860 5050 490.72 219 
1157.592 154.9 5020 7512 3013.26 989 
1215.577 9.5 974 7771 306.16 98 
1226.491 310 45755 5324 10666.22 5589 
1230.657 78.6 6481 5673 2797.55 1365 
1235.632 8.8 442 5770 324.16 146 
1240.507 43.7 4819 5988 1638.97 748 
1252.61 57.6 8138 6267 2302.44 1001 
1257.594 8.3 584 6392 336.45 157 
1283.516 304.5 201975 5188 13557.84 7904 
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1297.534 56.7 9325 5418 2650.78 1474 
1301.606 327 37872 4641 15354.88 10397 
1302.656 121.3 649 4738 5712.52 3089 
1315.61 25 1876 6374 1241.01 636 
1380.671 47.4 6952 6127 1331.58 770 
1386.677 82.2 7684 6772 2145.71 1166 
1400.643 25.2 2559 6040 594.07 372 
1408.637 22.8 1387 5964 519.03 290 
1411.622 46.4 9971 5175 1041.61 675 
1425.62 10.2 493 5121 213.51 149 
1462.824 19 2031 5554 324.66 210 
1467.739 15 1744 4862 249.89 195 
1585.745 45.4 2752 5070 559.27 496 
1612.733 47.9 4307 5708 593.34 516 
1634.686 7.6 744 6656 95.77 76 
1723.891 166 3263 4102 2219.3 2878 
1815.782 223.3 3127 4070 2546.65 3641 
2201.997 66.8 1448 3356 447.48 1020 
2215.958 17.2 1008 3403 99.16 244 
 
 
• Mascot search results 
Hit: Chain A, Crystal Structure of Lipid-Free Human Apolipoprotein A-I 
Match to: gi|90108664  
Score: 352  
Expect: 7.2e-30 
Nominal mass (Mr): 28061 
Calculated pI value: 5.27 
Taxonomy: Homo sapiens 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Number of mass values searched: 39 
Number of mass values matched: 26 
Sequence Coverage: 82% 
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ii. Band 2 
• Spectrum 
 
 
• Peak list (matches shown in bold) 
m/z SN Quality Fac. Res.  Intens. Area 
781.631 1283.9 1251616 5276 19429 3635 
831.614 254.7 161482 6216 3855 655 
869.699 364.2 339884 5980 5512 1052 
882.738 192.3 150811 5744 2910 579 
896.652 174.8 112843 6636 2645 448 
1012.704 730.6 529934 5769 11057 2385 
1031.637 459.6 350165 5948 6955 1518 
1165.812 68.7 44572 5967 1039 281 
1226.595 279.3 213233 4197 4226 1416 
1252.651 88 55691 5262 1332 402 
1283.588 200.9 124933 3914 3041 1107 
1301.668 477.4 289972 4144 7224 2603 
1386.7 50.5 35622 5185 764 265 
1400.639 59.2 37743 6214 896 266 
1448.865 22.3 14123 3918 338 145 
1462.767 9.3 4760 8417 140 33 
1562.836 6.1 3166 5758 92 32 
1612.606 16.9 11579 5987 255 92 
1677.58 7.9 4047 6849 120 38 
1731.817 5.2 5007 5688 78 46 
1812.685 8.6 2908 3634 130 58 
1904.545 5.7 2217 4737 86 37 
2202.49 5 1391 6818 76 30 
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• Mascot search results 
Hit: Chain A, Crystal Structure Of Lipid-Free Human Apolipoprotein A-I 
Match to: gi|90108664  
Score: 155  
Expect: 2.4e-10 
Nominal mass (Mr): 28061 
Calculated pI value: 5.27 
Taxonomy: Homo sapiens 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Number of mass values searched: 23 
Number of mass values matched: 12 
Sequence Coverage: 55% 
 
iv. Band 3 
• Spectrum 
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• Peak list (matches shown in bold) 
m/z SN Quality Fac. Res. Intens.  Area 
1051.806 9.1 6344 2462 155 75 
1102.014 9 3449 5089 153 39 
1165.886 14.1 12845 4717 241 91 
1456.892 27.5 21922 8014 469 125 
1550.932 135.7 99727 6181 2311 736 
1613.02 107.5 74479 6249 1832 601 
1641.018 13.2 8694 7982 225 69 
1670.989 43.8 27836 5858 746 248 
1732.341 6.3 3106 6826 108 36 
1914.209 31.2 21281 6709 532 209 
2179.178 22.6 12575 6789 385 161 
 
• Mascot search results 
Hit: SAA1 protein [Homo sapiens] 
Match to: gi|13937839  
Score: 110  
Expect: 7.6e-06 
Nominal mass (Mr): 13525 
Calculated pI value: 5.88 
Taxonomy: Homo sapiens 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Number of mass values searched: 11 
Number of mass values matched: 6 
Sequence Coverage: 63% 
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6.4.2 Expanded results for Table 3.6 
i. Band 1 
• Spectrum 
 
 
• Peak list (matches shown in bold) 
m/z SN Quality Fac. Res. Intens. Area 
811.581 11 910 6232 224.47 50 
882.719 10.8 477 8664 218.79 39 
927.651 237.4 6869 9299 4589.44 890 
941.654 13.2 442 8157 249.13 52 
949.626 11.4 587 6197 217.15 54 
960.727 181.1 12844 8577 3402.86 696 
982.705 17.9 2031 8710 326.21 76 
1022.75 16.1 428 7278 273.22 77 
1035.747 39.2 2461 8588 667.88 153 
1051.727 14.3 665 6891 236.06 75 
1057.724 8.9 652 8222 150.7 37 
1074.721 25.1 1193 8397 404.93 95 
1149.798 44.8 13168 7990 571.22 188 
1165.925 9.9 603 7473 126.08 38 
1171.774 13 379 10906 158.85 44 
1226.812 16.1 1515 8044 177.05 59 
1468.086 38.1 3486 7389 343.84 184 
1624.016 19.3 1758 5965 165.15 127 
1640.174 47.4 2046 5645 398.57 315 
1733.391 6.9 268 9615 44.42 30 
2046.439 6.7 151 13318 32.64 29 
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• Mascot search results 
Hit 1: Albumin-like [Homo sapiens] 
Match to: gi|763431  
Score: 91  
Expect: 0.0009 
Nominal mass (Mr): 52048  
Calculated pI value: 5.69 
Taxonomy: Homo sapiens 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Number of mass values searched: 21 
Number of mass values matched: 8 
Sequence Coverage: 16% 
 
 
Hit 2: Albumin, isoform CRA_t [Homo sapiens] 
 Match to: gi|119626083  
 Score: 86  
 Expect: 0.0027 
 Nominal mass (Mr): 58614  
 Calculated pI value: 6.66 
 Taxonomy: Homo sapiens 
 Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
 Number of mass values searched: 21 
 Number of mass values matched: 8 
 Sequence Coverage: 14%
 
Hit 3: Chain A, Structure Of Human Serum Albumin With S-Naproxen 
 And The Ga Module 
 Match to: gi|168988718  
 Score: 86  
 Expect: 0.0032 
 Nominal mass (Mr): 65778 
 Calculated pI value: 5.63 
 Taxonomy: Homo sapiens 
Appendices  98 
 Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
 Number of mass values searched: 21 
 Number of mass values matched: 8 
 Sequence Coverage: 12% 
 
ii. Band 2 
• Spectrum 
 
 
 
• Peak list (matches shown in bold) 
     
m/z SN Quality Fac. Res. Intens. Area 
822.571 44.2 1264 9343 1122.83 182 
836.563 12.4 573 7178 336.53 69 
842.625 32.8 348 7617 919.23 184 
844.607 179.5 14521 6870 5079.87 1090 
858.604 11.2 330 4703 339.56 108 
861.177 13 380 9448 405.81 61 
864.613 10 275 8088 303.48 61 
866.589 27.2 4691 6585 830.19 180 
886.515 18.1 269 8726 463.88 96 
980.582 61.1 4450 8832 988.36 220 
1032.704 144.7 24796 8202 2276.09 573 
1239.667 18.2 1938 7290 203.88 84 
1552.846 13.2 1405 7754 115.46 67 
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• Mascot search results  
Hit:  Fibrinogen beta chain, isoform CRA_f [Homo sapiens] 
  Match to: gi|119625340  
  Score: 82  
   Expect: 0.0064 
   Nominal mass (Mr): 44153 
   Calculated pI value: 8.84 
   Taxonomy: Homo sapiens 
   Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
  Number of mass values searched: 13 
   Number of mass values matched: 7 
   Sequence Coverage: 13% 
 
iii. Band 3 
• Spectrum 
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• Peak list (matches shown in bold) 
 
m/z SN Quality Fac. Res. Intens. Area 
861.168 62.8 2535 6988 1282.66 252 
877.145 47.7 1402 9345 902.01 167 
1034.655 60.1 3340 8636 741.67 177 
1117.685 19.9 1369 7432 238.09 73 
1164.763 11.4 137 11919 131.61 36 
1186.77 9 498 8119 96.91 28 
1491.911 10.4 786 7960 79.75 40 
1513.932 8.3 554 6790 63.13 39 
1546.011 9.1 820 6417 69.8 43 
1683.194 24.7 1422 5118 169.11 150 
1873.21 25.2 574 5294 167.61 184 
 
• Mascot search results 
Hit: Chain C, Crystal Structure Of Recombinant Human Fibrinogen 
 Fragment D 
 Match to: gi|24987625 Score: 82 Expect: 0.0065 
 Nominal mass (Mr): 35155 
 Calculated pI value: 5.86 
 Taxonomy: Homo sapiens 
 Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
 Number of mass values searched: 11 
 Number of mass values matched: 6 
 Sequence Coverage: 23% 
  
 
 
 
 
 
Appendices  101 
6.5 Sequencing results 
 
Different combinations of the T436K and D432E genotypes produce the 
Gc isoforms, as indicated in Table 6.1.  
 
Table 6.1 – Association between SNP alleles and Gc isoforms in DBP 
 
Gc isoform Alleles 
Gc1S-1S EE/TT 
Gc1S-1F DE/TT 
Gc1F-1F DD/TT 
Gc1S-2 DE/TK 
Gc1F-2 DD/TK 
Gc2-2 DD/KK 
 
The relevant part of exon 11, containing both SNP sites (underlined) is:  
 
AAAATTGCC TGATGCCACA CCCACGGAAC TGGCAAAGCT GGTTAACAAG CACTCAGACT 
     1    2   
 
Both SNPs trigger an amino acid substitution, as follows (changed nucleotide 
underlined): 
 
D432E (site 1): 
GAT = D allele (i.e. Aspartic acid) 
GAG = E allele (i.e. Glutamic acid) 
 
T436K (site 2): 
ACG = T allele (i.e. Threonine) 
AAG = K allele (i.e. Lysine) 
 
The sequences of four individuals are included below, including 
the relevant section of each electropherogram. The codons responsible 
for determining the D432E and T436K alleles are underlined and in 
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bold. It should be noted that the poor sequencing results in the sample 
from lane 4 are expected, because this individual does not have a 
mutant allele. 
 
6.5.1 Sequences and electropherograms – Multiplex protocol 
 
From Figure 3.11 – Lane 1 
ATTCATCACAGGTATAGATACTTAGGAGAAGGCAATAAAATATCCCCACCCCATCTAAAAGATCAG
AAACGGCTATTATTTTGCATTAGAAATTAGTATAAAATAAATACAAGTAGTAAGACCTTACATTTA
AAAGGTTTTTCAGACAGGCAGAGCGACTAAAAGCAAAATTGCCTGATGCCACACCCACGGTACAGC
AAAGCTGGTAGACAAGCATCAGACTTTGCATTTGCTTTTAGTCGCTCTGCGTCTGAATACATTTAA
TGTAGGTCTTCTACTGTAGTTATTTTATACAATTTCTAATGCAAATAATAGCTTTCGATCTTTTCA
TAAAATGAAAATGAAATACTTGCTGTCTCAGAAATTCTGTACTGTGGTATAGAAATCATTTGAGAT
CAAAATGAAACTGCCA 
 
 
 
From Figure 3.11 – Lane 2 
CGATCAAGGTTAGAATTTTCTTGAGACAGGCAAGTATTTCTATTTTCATTTTTATTGTAAAAGATC
TGAAATGGCTATTATTTTGCATTAGAAATTTGTATAAAATAAATACATGTAGTAAGACCTTACATT
TAAATGGTTTTTCAGACTGGCAGAGCGACTAAAAGCAAAATTGCCTGAGGCCACACCCACGGTACT
GAAAAGCTGGTTGAGTGGGTGTGGCTCAGCATTTTGCTTTTAGTCGCTCTGCGTCTGAAAACATTT
AATGTAGGTCTTACTACTGTATTTATTTTATACAATTTCTATGCAAATAATAGCTTTCGATCTTTT
CATAAAATGAAATGAAATACTTGCTGTCTCAGAAATTCTATACCTGTGGTATAGAAAGTCATTTGA
GATCAAAAATGAAACATGCCA 
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6.5.2 Sequences and electropherograms – Touchdown Protocol 
 
From Figure 3.13 – Lane 1 (Mutant Reverse) 
GATCATACACAGGTAAGATTTTCTTGAGACAGGCAAGTATTTCTATTTTCATTTTTATTGTAAAAG
ATCTGAAATGGCTATTATTTTGCATTAGAAATTTGTATAAAATAAATACATGTAGTAAGACCTTAC
ATTTAAATGGTTTTTCAGACTGGCAGAGCGACTAAAAGCAAAATTGCCTGATGCCACACCCAAGCA
ACAGGCAAAGCAGCATAACAAGCACACAGACTTTGC 
 
  
 
From Figure 3.13 – Lane 2 (Wild-type Reverse) 
CAATTCAACACAGGTAAGATTTTCTTGAGACAGGCAAGTATTTCTATTTTCATTTTTATTGTAAAA
GATCTGAAATGGCTATTATTTTGCATTAGAAATTTGTATAAAATAAATACATGTAGTAAGACCTTA
CATTTAAATGGTTTTTCAGACTGGCAGAGCGACTAAAAGCAAAATTGCCTGAGGCCACACCCACGG
AACAGGCAAAGCAGGT 
 
  
Note: The individual from lanes 1 and 2 therefore has the genotype DETK 
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From Figure 3.13 – Lane 4 (Mutant Reverse) 
AAAGGGGGGCGGTTGGGTTTGTAATCCGGGCGCAGACCTGGCTTTCTTGGGCTCGTTCGGCGGGGG
GTTAGGCGTCGGCTTGGCTGTCTAAAGGGGGTGAATGAGGTGGTGTGTAGCTTTTCTTAAAGGGGT
CACCGCGGAATTGCTGATCTGCTTTTATTGAGGGTCCGTTTCTCTGTATCGTGCGGTGACCC 
 
  
 
From Figure 3.13 – Lane 5 (Wild-type Reverse) 
CATTCAAACACAGGTAAGATTTTCTTGAGACAGGCAAGTATTTCTATTTTCATTTTTATTGTAAAA
GATCTGAAATGGCTATTATTTTGCATTAGAAATTTGTATAAAATAAATACATGTAGTAAGACCTTA
CATTTAAATGGTTTTTCAGACTGGCAGAGCGACTAAAAGCAAAATTGCCTGATGCCACACCCACGG
AACAGGCAAAGCAGGT 
 
 
 
Note: The individual from lanes 4 and 5 therefore has the genotype DDTT 
 
